<document page-count="43">
<page number="1">
<table data-filename="Qian Chen - 2014 - NANOTUBES AS CARRIERS OF NUCLEIC ACIDS INTO CELLS , Patent App(2).pdf" data-page="1" data-table="1"><tr><td></td><td></td><td></td><td></td><td></td><td>US 201401.71482A1</td><td></td><td></td><td></td></tr><tr><td colspan="3">(19) United States</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="4">(12) Patent Application Publication</td><td colspan="5">(10) Pub. No.: US 2014/0171482 A1</td></tr><tr><td></td><td colspan="2">Webster et al.</td><td></td><td style="text-align: right">(43)</td><td>Pub. Date:</td><td colspan="2">Jun. 19,9</td><td style="text-align: right">2014</td></tr><tr><td style="text-align: right">(54)</td><td colspan="2">NANOTUBES AS CARRIERS OF NUCLEIC</td><td></td><td></td><td colspan="2">Publication Classification</td><td></td><td></td></tr><tr><td></td><td colspan="2">ACDS INTO CELLS</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">(75)</td><td>Inventors:</td><td>Thomas J. Webster, Barrington, RI</td><td style="text-align: right">(51)</td><td>Int. Cl.</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>(US); Qian Chen, Barrington, RI (US);</td><td></td><td>CI2N 15/87</td><td style="text-align: right" colspan="2">(2006.01)</td><td></td><td></td></tr><tr><td></td><td></td><td>Yupeng Chen, Mansfield, MA (US)</td><td></td><td>CI2N 15/I 15</td><td style="text-align: right" colspan="2">(2006.01)</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>CI2O I/68</td><td style="text-align: right" colspan="2">(2006.01)</td><td></td><td></td></tr><tr><td style="text-align: right">(73)</td><td colspan="2">Assignees: RHODE ISLAND HOSPITAL,</td><td></td><td>A613 L/713</td><td style="text-align: right" colspan="2">(2006.01)</td><td></td><td></td></tr><tr><td></td><td></td><td>Providence, RI (US); Brown University,</td><td></td><td>A647/48</td><td style="text-align: right" colspan="2">(2006.01)</td><td></td><td></td></tr><tr><td></td><td></td><td>Providence, RI (US)</td><td style="text-align: right">(52)</td><td>U.S. Cl.</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>CPC ..............</td><td colspan="4">CI2N 15/87 (2013.01); A61 K3I/713</td></tr><tr><td style="text-align: right">(21)</td><td>Appl. No.:</td><td style="text-align: right">13/977,138</td><td></td><td></td><td colspan="4">(2013.01); A61K 47/48061 (2013.01); C12O</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="4">I/6841 (2013.01); C12N 15/115 (2013.01)</td></tr><tr><td style="text-align: right">(22)</td><td>PCT Filed:</td><td>Jan. 3, 2012</td><td></td><td>USPC</td><td colspan="4">.......... 514/44. A 435/375; 435/455; 435/471;</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td style="text-align: right" colspan="4">435/252.1435/6.11536/24.5</td></tr><tr><td style="text-align: right">(86).</td><td>PCT No.:</td><td>PCT/US12A2O056</td><td></td><td></td><td></td><td>s</td><td>s</td><td></td></tr><tr><td></td><td>S371 (c)(1),</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>(2), (4) Date:</td><td>Feb. 25, 2014</td><td style="text-align: right">(57)</td><td></td><td>ABSTRACT</td><td></td><td></td><td></td></tr><tr><td></td><td colspan="2">Related U.S. Application Data</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">(60)</td><td colspan="2">Provisional application No. 61/429,555, filed on Jan.</td><td colspan="6">The present invention is directed to transfection complexes of</td></tr><tr><td></td><td style="text-align: right">4, 2011.</td><td></td><td colspan="5">rosette nanotubes and one or more nucleic acids.</td><td></td></tr></table></page>
<page number="2">
<table data-filename="Qian Chen - 2014 - NANOTUBES AS CARRIERS OF NUCLEIC ACIDS INTO CELLS , Patent App(2).pdf" data-page="2" data-table="1"><tr><td>Patent Application Publication Jun. 19, 2014 Sheet 1 of 24 US 2014/0171482 A1</td></tr><tr><td>XXXX-XXXxxxx.</td></tr></table></page>
<page number="3">
<table data-filename="Qian Chen - 2014 - NANOTUBES AS CARRIERS OF NUCLEIC ACIDS INTO CELLS , Patent App(2).pdf" data-page="3" data-table="1"><tr><td colspan="2">Patent Application Publication</td><td colspan="2">Jun. 19, 2014</td><td colspan="2">Sheet 2 of 24</td><td>US 2014/0171482 A1</td></tr><tr><td>FIG.2</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">---- RNT</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">a - RNA</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">- RNTIRNA</td><td></td></tr><tr><td style="text-align: right">0.4</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">200</td><td style="text-align: right">220</td><td style="text-align: right">240</td><td style="text-align: right">260</td><td style="text-align: right">280</td><td style="text-align: right">300</td><td style="text-align: right">320</td></tr><tr><td style="text-align: right">200</td><td style="text-align: right">220</td><td style="text-align: right">240</td><td style="text-align: right">260</td><td style="text-align: right">280</td><td style="text-align: right">300</td><td style="text-align: right">320</td></tr><tr><td></td><td></td><td colspan="3">Wavelength/nm</td><td></td><td></td></tr></table></page>
<page number="4">
<table data-filename="Qian Chen - 2014 - NANOTUBES AS CARRIERS OF NUCLEIC ACIDS INTO CELLS , Patent App(2).pdf" data-page="4" data-table="1"><tr><td colspan="2">Patent Application Publication</td><td colspan="2">Jun. 19, 2014</td><td colspan="2">Sheet 3 of 24</td><td>US 2014/0171482 A1</td></tr><tr><td></td><td></td><td></td><td></td><td style="text-align: right">- - - -</td><td>RNT</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">- RNTIRNA</td><td></td></tr><tr><td style="text-align: right">200</td><td style="text-align: right">220</td><td style="text-align: right">240</td><td style="text-align: right">260</td><td style="text-align: right">280</td><td style="text-align: right">300</td><td style="text-align: right">320</td></tr><tr><td></td><td></td><td colspan="3">Wavelength (nm)</td><td></td><td></td></tr><tr><td></td><td></td><td colspan="3">- RNTIRNA</td><td></td><td></td></tr><tr><td style="text-align: right">5.0</td><td></td><td colspan="4">- RNT signal + RNA signal</td><td></td></tr><tr><td style="text-align: right">4.5</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">4.0</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">3.5</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">3.0</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">2.5</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">2.0</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">15</td><td></td><td></td><td></td><td></td><td>a8</td><td style="text-align: right">.</td></tr><tr><td style="text-align: right">1.0</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">0.5</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>O.0</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">200</td><td style="text-align: right">220</td><td style="text-align: right">240</td><td style="text-align: right">260</td><td>28O</td><td style="text-align: right">300</td><td style="text-align: right">320</td></tr><tr><td></td><td></td><td colspan="3">Wavelength (nm)</td><td></td><td></td></tr></table></page>
<page number="5">
<table data-filename="Qian Chen - 2014 - NANOTUBES AS CARRIERS OF NUCLEIC ACIDS INTO CELLS , Patent App(2).pdf" data-page="5" data-table="1"><tr><td colspan="3">Patent Application Publication</td><td colspan="2">Jun. 19, 2014</td><td>Sheet 4 of 24</td><td>US 2014/0171482 A1</td></tr><tr><td>FIG. 4</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">mara RNTS</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="4">-- First derivative of UV absorbance CUWE</td></tr><tr><td style="text-align: right">0.</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>O</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>O</td><td style="text-align: right">20</td><td style="text-align: right">40</td><td style="text-align: right">60</td><td style="text-align: right">80</td><td style="text-align: right">100</td></tr><tr><td></td><td></td><td></td><td colspan="2">Temperature (C)</td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">mam RN/RNA</td><td></td><td></td><td></td></tr><tr><td></td><td style="text-align: right">320</td><td colspan="5">-- First derivative of UV absorbance curve</td></tr><tr><td></td><td style="text-align: right">()</td><td style="text-align: right">20</td><td style="text-align: right">40</td><td style="text-align: right">60</td><td style="text-align: right">80 100</td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">Temperature (C)</td><td></td><td></td></tr></table></page>
<page number="6">
<table data-filename="Qian Chen - 2014 - NANOTUBES AS CARRIERS OF NUCLEIC ACIDS INTO CELLS , Patent App(2).pdf" data-page="6" data-table="1"><tr><td>Patent Application Publication</td><td>Jun. 19, 2014</td><td>Sheet 5 of 24</td><td>US 2014/0171482 A1</td></tr></table></page>
<page number="7">
<table data-filename="Qian Chen - 2014 - NANOTUBES AS CARRIERS OF NUCLEIC ACIDS INTO CELLS , Patent App(2).pdf" data-page="7" data-table="1"><tr><td>Patent Application Publication</td><td>Jun. 19, 2014</td><td>Sheet 6 of 24</td><td>US 2014/0171482 A1</td></tr></table></page>
<page number="8">
<table data-filename="Qian Chen - 2014 - NANOTUBES AS CARRIERS OF NUCLEIC ACIDS INTO CELLS , Patent App(2).pdf" data-page="8" data-table="1"><tr><td>Patent Application Publication</td><td>Jun. 19, 2014</td><td>Sheet 7 of 24</td><td>US 2014/0171482 A1</td></tr></table></page>
<page number="9">
<table data-filename="Qian Chen - 2014 - NANOTUBES AS CARRIERS OF NUCLEIC ACIDS INTO CELLS , Patent App(2).pdf" data-page="9" data-table="1"><tr><td>Patent Application Publication</td><td>Jun. 19, 2014</td><td>Sheet 8 of 24</td><td>US 2014/0171482 A1</td></tr></table></page>
<page number="10">
<table data-filename="Qian Chen - 2014 - NANOTUBES AS CARRIERS OF NUCLEIC ACIDS INTO CELLS , Patent App(2).pdf" data-page="10" data-table="1"><tr><td>Patent Application Publication</td><td>Jun. 19, 2014</td><td>Sheet 9 of 24</td><td>US 2014/0171482 A1</td></tr></table></page>
<page number="11">
<table data-filename="Qian Chen - 2014 - NANOTUBES AS CARRIERS OF NUCLEIC ACIDS INTO CELLS , Patent App(2).pdf" data-page="11" data-table="1"><tr><td>Patent Application Publication</td><td>Jun. 19, 2014</td><td>Sheet 10 of 24</td><td>US 2014/0171482 A1</td></tr><tr><td>*** &amp; * *</td><td></td><td></td><td></td></tr><tr><td></td><td>#c *</td><td></td><td></td></tr></table></page>
<page number="12">
<table data-filename="Qian Chen - 2014 - NANOTUBES AS CARRIERS OF NUCLEIC ACIDS INTO CELLS , Patent App(2).pdf" data-page="12" data-table="1"><tr><td>Patent Application Publication</td><td>Jun. 19, 2014</td><td>Sheet 11 of 24</td><td>US 2014/0171482 A1</td></tr><tr><td></td><td style="text-align: right">1.2</td><td></td><td></td></tr><tr><td style="text-align: right">5</td><td></td><td></td><td></td></tr><tr><td></td><td style="text-align: right">0.9</td><td></td><td></td></tr><tr><td style="text-align: right">9.</td><td></td><td></td><td></td></tr><tr><td>x</td><td></td><td></td><td></td></tr><tr><td></td><td style="text-align: right">0.6</td><td></td><td></td></tr><tr><td>c</td><td></td><td></td><td></td></tr><tr><td>Y</td><td></td><td></td><td></td></tr><tr><td>E</td><td style="text-align: right">0.3</td><td></td><td></td></tr><tr><td>1.11 E-15</td><td></td><td></td><td></td></tr><tr><td></td><td>Controls</td><td>RNTs+ miR365</td><td></td></tr><tr><td></td><td>(scrambled</td><td>inhibitor</td><td></td></tr><tr><td></td><td>RNA)</td><td></td><td></td></tr><tr><td></td><td colspan="2">F.G. 12A</td><td></td></tr><tr><td></td><td style="text-align: right">1.2</td><td></td><td></td></tr><tr><td>C</td><td></td><td></td><td></td></tr><tr><td></td><td style="text-align: right">0.9</td><td></td><td></td></tr><tr><td>g</td><td></td><td></td><td></td></tr><tr><td>O.</td><td></td><td></td><td></td></tr><tr><td></td><td style="text-align: right">0.6</td><td></td><td></td></tr><tr><td>c</td><td></td><td></td><td></td></tr><tr><td style="text-align: right">1.</td><td></td><td></td><td></td></tr><tr><td>E</td><td style="text-align: right">0.3</td><td></td><td></td></tr><tr><td>-1.11 E-15</td><td></td><td></td><td></td></tr><tr><td></td><td>Controls</td><td>TBLS+ miR365</td><td></td></tr><tr><td></td><td>(scrambled</td><td>inhibitor</td><td></td></tr><tr><td></td><td>RNA)</td><td></td><td></td></tr><tr><td></td><td colspan="2">FIG. 12B</td><td></td></tr></table></page>
<page number="13">
<table data-filename="Qian Chen - 2014 - NANOTUBES AS CARRIERS OF NUCLEIC ACIDS INTO CELLS , Patent App(2).pdf" data-page="13" data-table="1"><tr><td>Patent Application Publication</td><td>Jun. 19, 2014</td><td>Sheet 12 of 24</td><td>US 2014/0171482 A1</td></tr></table></page>
<page number="14">
<table data-filename="Qian Chen - 2014 - NANOTUBES AS CARRIERS OF NUCLEIC ACIDS INTO CELLS , Patent App(2).pdf" data-page="14" data-table="1"><tr><td>Patent Application Publication</td><td>Jun. 19, 2014</td><td>Sheet 13 of 24</td><td>US 2014/0171482 A1</td></tr></table></page>
<page number="15">
<table data-filename="Qian Chen - 2014 - NANOTUBES AS CARRIERS OF NUCLEIC ACIDS INTO CELLS , Patent App(2).pdf" data-page="15" data-table="1"><tr><td>Patent Application Publication</td><td>Jun. 19, 2014</td><td>Sheet 14 of 24</td><td>US 2014/0171482 A1</td></tr></table></page>
<page number="16">
<table data-filename="Qian Chen - 2014 - NANOTUBES AS CARRIERS OF NUCLEIC ACIDS INTO CELLS , Patent App(2).pdf" data-page="16" data-table="1"><tr><td>Patent Application Publication</td><td>Jun. 19, 2014</td><td>Sheet 15 of 24</td><td>US 2014/0171482 A1</td></tr></table></page>
<page number="17">
<table data-filename="Qian Chen - 2014 - NANOTUBES AS CARRIERS OF NUCLEIC ACIDS INTO CELLS , Patent App(2).pdf" data-page="17" data-table="1"><tr><td>Patent Application Publication</td><td>Jun. 19, 2014</td><td>Sheet 16 of 24</td><td>US 2014/0171482 A1</td></tr></table></page>
<page number="18">
<table data-filename="Qian Chen - 2014 - NANOTUBES AS CARRIERS OF NUCLEIC ACIDS INTO CELLS , Patent App(2).pdf" data-page="18" data-table="1"><tr><td>Patent Application Publication Jun. 19, 2014 Sheet 17 of 24 US 2014/0171482 A1</td></tr><tr><td>?$</td></tr></table></page>
<page number="19">
<table data-filename="Qian Chen - 2014 - NANOTUBES AS CARRIERS OF NUCLEIC ACIDS INTO CELLS , Patent App(2).pdf" data-page="19" data-table="1"><tr><td>Patent Application Publication Jun. 19, 2014 Sheet 18 of 24 US 2014/0171482 A1</td></tr><tr><td style="text-align: right">$</td></tr></table></page>
<page number="20">
<table data-filename="Qian Chen - 2014 - NANOTUBES AS CARRIERS OF NUCLEIC ACIDS INTO CELLS , Patent App(2).pdf" data-page="20" data-table="1"><tr><td>Patent Application Publication</td><td>Jun. 19, 2014</td><td>Sheet 19 of 24</td><td>US 2014/0171482 A1</td></tr></table></page>
<page number="21">
<table data-filename="Qian Chen - 2014 - NANOTUBES AS CARRIERS OF NUCLEIC ACIDS INTO CELLS , Patent App(2).pdf" data-page="21" data-table="1"><tr><td>Patent Application Publication</td><td>Jun. 19, 2014</td><td>Sheet 20 of 24</td><td>US 2014/0171482 A1</td></tr></table></page>
<page number="22">
<table data-filename="Qian Chen - 2014 - NANOTUBES AS CARRIERS OF NUCLEIC ACIDS INTO CELLS , Patent App(2).pdf" data-page="22" data-table="1"><tr><td>Patent Application Publication</td><td>Jun. 19, 2014</td><td>Sheet 21 of 24</td><td>US 2014/0171482 A1</td></tr></table></page>
<page number="23">
<table data-filename="Qian Chen - 2014 - NANOTUBES AS CARRIERS OF NUCLEIC ACIDS INTO CELLS , Patent App(2).pdf" data-page="23" data-table="1"><tr><td colspan="3">Patent Application Publication</td><td colspan="2">Jun. 19, 2014</td><td colspan="2">Sheet 22 of 24 US 2014/0171482 A1</td></tr><tr><td>E</td><td>0. O O4</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>Beacon only</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>RNTIBeacon</td></tr><tr><td></td><td>30 mins</td><td>1 day</td><td>3 days</td><td>5 days</td><td>7 days</td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">FIG. 23</td><td></td><td></td></tr><tr><td></td><td>siRNA only</td><td></td><td></td><td>RNTIRNA</td><td></td><td>Lipofectamine?RNA</td></tr><tr><td></td><td></td><td></td><td>:</td><td></td><td>O</td><td>s.</td></tr><tr><td colspan="3">ozoano sooooooo 10</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>FSCH</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">siRNAonly 1.31%</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">positive Cells</td><td></td><td></td><td></td><td></td><td></td></tr></table></page>
<page number="24">
<table data-filename="Qian Chen - 2014 - NANOTUBES AS CARRIERS OF NUCLEIC ACIDS INTO CELLS , Patent App(2).pdf" data-page="24" data-table="1"><tr><td>Patent Application Publication</td><td>Jun. 19, 2014</td><td>Sheet 23 of 24</td><td>US 2014/0171482 A1</td></tr></table></page>
<page number="25">
<table data-filename="Qian Chen - 2014 - NANOTUBES AS CARRIERS OF NUCLEIC ACIDS INTO CELLS , Patent App(2).pdf" data-page="25" data-table="1"><tr><td>Patent Application Publication</td><td>Jun. 19, 2014</td><td>Sheet 24 of 24</td><td>US 2014/0171482 A1</td></tr><tr><td style="text-align: right">25</td><td></td><td></td><td></td></tr><tr><td style="text-align: right">20</td><td></td><td></td><td></td></tr><tr><td>Controls</td><td>Lipofectamine</td><td>TBLS</td><td>RNTS</td></tr><tr><td></td><td>--miR365</td><td>+miR365</td><td>+miR365</td></tr><tr><td></td><td>mimic</td><td>mimic</td><td>mimic</td></tr><tr><td></td><td>FG. 26</td><td></td><td></td></tr></table></page>
<page number="26">
<table data-filename="Qian Chen - 2014 - NANOTUBES AS CARRIERS OF NUCLEIC ACIDS INTO CELLS , Patent App(2).pdf" data-page="26" data-table="1"><tr><td colspan="2">US 2014/0171482 A1</td><td></td><td></td><td></td><td></td><td>Jun. 19, 2014</td></tr><tr><td colspan="4">NANOTUBES AS CARRIERS OF NUCLEC</td><td></td><td colspan="2">Highly branched HK peptides have also been Suggested as</td></tr><tr><td></td><td colspan="2">ACDS INTO CELLS</td><td></td><td></td><td colspan="2">carriers of siRNA to transfect eukaryotic cells. See U.S. Pat.</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">No. 7,772.201.</td></tr><tr><td></td><td colspan="3">RELATED APPLICATION DATA</td><td></td><td style="text-align: right">0006.</td><td>The lipophilic nature of biological membranes</td></tr><tr><td style="text-align: right">0001.</td><td colspan="4">This application claims priority to U.S. Provisional</td><td colspan="2">restricts direct intracellular delivery of potential drugs or</td></tr><tr><td colspan="5">Patent Application No. 61/429,555, filed on Jan. 4, 2012 and</td><td colspan="2">molecular probes. There is a need in the art for transfection</td></tr><tr><td colspan="5">is hereby incorporated herein by reference in its entirety for</td><td colspan="2">complexes having transfection efficiencies sufficient to</td></tr><tr><td colspan="2">all purposes.</td><td></td><td></td><td></td><td colspan="2">deliver small RNA into the interior of cells, such as therapeu</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">tically effective amounts of siRNA into target cells. There is</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">also a need in the art for carriers that are stable in serum for</td></tr><tr><td colspan="4">STATEMENT OF GOVERNMENT INTERESTS</td><td></td><td colspan="2">delivery systems to be effective both in vitro and in vivo.</td></tr><tr><td style="text-align: right">0002</td><td colspan="4">This invention was made with government support</td><td style="text-align: right">0007.</td><td>It is a further object of the present invention to create</td></tr><tr><td>under</td><td colspan="4">National Institutes of Health grant number NIH</td><td colspan="2">complexes of RNA with rosette nanotubes that can be deliv</td></tr><tr><td colspan="2">P2ORRO24484 and R21 AGO27521.</td><td>The</td><td>Government</td><td>has</td><td colspan="2">ered into target cells where the RNA can then function to</td></tr><tr><td colspan="2">certain rights in the invention.</td><td></td><td></td><td></td><td colspan="2">silence certain RNA and thereby prevent expression of an</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">associated protein or proteins. It is a further object of the</td></tr><tr><td></td><td>FIELD</td><td></td><td></td><td></td><td colspan="2">present invention to provide methods of treating individuals</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">using a delivery system of a complex of RNA with a rosette</td></tr><tr><td style="text-align: right">0003</td><td colspan="4">Embodiments of the present disclosure relate to the</td><td colspan="2">nanotube which transfects cells of the individual in a manner</td></tr><tr><td colspan="5">use of rosette nanotubes to deliver nucleic acids into cells.</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">to prevent expression of an associated protein or proteins.</td></tr><tr><td colspan="5">Embodiments of the present disclosure still further relate to</td><td></td><td></td></tr><tr><td colspan="5">complexes of rosette nanotubes and nucleic acids and com</td><td colspan="2">These and other objects, features, and advantages of the</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">invention or certain embodiments of the invention will be</td></tr><tr><td colspan="5">positions thereof and the use of such complexes to delivernucleic acids into the cells of individuals for therapeutic</td><td colspan="2">apparent to those skilled in the art from the following disclo</td></tr><tr><td colspan="5">purposes. Embodiments of the present disclosure further</td><td colspan="2">Sure and description of exemplary embodiments.</td></tr><tr><td colspan="5">relate to the use of rosette nanotubes to deliver interference</td><td></td><td></td></tr><tr><td colspan="5">RNA into cells. Embodiments of the present disclosure fur</td><td></td><td>SUMMARY</td></tr><tr><td colspan="5">ther relate to methods of inhibiting target RNA within a cell</td><td style="text-align: right">0008</td><td>Embodiments of the present disclosure are directed</td></tr><tr><td>using</td><td colspan="4">complexes of rosette nanotubes and Small RNA.</td><td colspan="2">to methods of transfecting cells with nucleic acids or poly</td></tr><tr><td colspan="5">Embodiments of the present disclosure still further relate to</td><td colspan="2">nucleotides such as DNA or RNA, such as small RNA and its</td></tr><tr><td colspan="5">transfection complexes of rosette nanotubes and nucleic acids</td><td colspan="2">derivatives, mimic, and inhibitors. RNA according to aspects</td></tr><tr><td colspan="5">such as DNA and RNA and compositions thereof and the use</td><td colspan="2">of the present disclosure includes a duplex of nucleic acids of</td></tr><tr><td colspan="5">of such transfection complexes to introduce the DNA or RNA</td><td colspan="2">between about 10 to about 30 nucleotides. Embodiments of</td></tr><tr><td colspan="4">into cells, for example as a therapeutic treatment.</td><td></td><td colspan="2">the present disclosure include the formation of a composite or</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">complex or combination of one or more nucleic acids, such as</td></tr><tr><td></td><td colspan="2">BACKGROUND</td><td></td><td></td><td colspan="2">RNA, and a rosette nanotube where the one or more nucleic</td></tr><tr><td style="text-align: right">0004</td><td colspan="4">RNA interference (RNAi) is a system in living cells</td><td colspan="2">acids are attached to or otherwise bound to the rosette nano</td></tr><tr><td colspan="5">that helps control genes activity. Mediators of RNAi include</td><td colspan="2">tube. Embodiments of the present disclosure are further</td></tr><tr><td colspan="5">two classes of small RNA including microRNA (miRNA) and</td><td colspan="2">directed to a product made by the process of mixing together</td></tr><tr><td colspan="5">small interfering RNA (siRNA). Interference RNA molecules</td><td colspan="2">rosette nanotubes as described herein or modules forming</td></tr><tr><td colspan="5">have been used to silence genes and consequently their gene</td><td colspan="2">rosette nanotubes as described herein and one or more nucleic</td></tr><tr><td colspan="5">products and more efficiently than antisense RNA alone. See</td><td colspan="2">acids in aqueous media under conditions which cause the</td></tr><tr><td colspan="5">Rocheleau CE, et al., Cell 1997: 90:707-716.) Interference</td><td colspan="2">rosette nanotubes to combine with the one or more nucleic</td></tr><tr><td colspan="5">RNA molecules have been used to study the role of proteins in</td><td colspan="2">acids to form a complex or combination in aqueous media</td></tr><tr><td colspan="5">signal transduction pathways and it has also been Suggested</td><td colspan="2">where the one or more nucleic acids are attached or otherwise</td></tr><tr><td colspan="5">that these molecules might be useful in treating a variety of</td><td colspan="2">bound through steric, ionic, covalent or other forces to the</td></tr><tr><td colspan="5">diseases in which the causative protein is overexpressed. See</td><td colspan="2">rosette nanotube.</td></tr><tr><td colspan="5">Arenz et al., Naturwissenschafien 2003: 90:345-359; Coburn</td><td style="text-align: right">0009</td><td>Embodiments further include delivering the com</td></tr><tr><td colspan="5">et al., J Antimicrob Chemother 2003; 51:753-756. To avoid</td><td colspan="2">posite into living cells. Embodiments further include a</td></tr><tr><td colspan="3">nonspecific gene silencing induced by</td><td colspan="2">longer double</td><td colspan="2">method of treating an individual requiring treatment compris</td></tr><tr><td colspan="5">stranded RNA, small interfering RNAs, a duplex of 21-23</td><td colspan="2">ing administering a complex of a rosette nanotube and one or</td></tr><tr><td colspan="5">nucleotides, have been used as mediators to degrade target</td><td colspan="2">more nucleic acids to the individual in a manner to transfect</td></tr><tr><td colspan="5">mRNA. See Fire et al., Nature 1998; 391:806-811.) Once</td><td colspan="2">cells within the individual with the one or more nucleic acids.</td></tr><tr><td colspan="5">inside the cell, siRNA is incorporated into an RNA-induced</td><td colspan="2">Embodiments further include a method of treating an indi</td></tr><tr><td colspan="5">silence complex (RISC), a protein-RNA complex that results</td><td colspan="2">vidual requiring treatment comprising administering a com</td></tr><tr><td colspan="5">in unwinding and strand separation of the RNA duplex. The</td><td colspan="2">plex of a rosette nanotube and one or more nucleic acids to the</td></tr><tr><td colspan="5">antisense RNA then guides the activated RISC to anneal and</td><td colspan="2">individual in a manner to transfect cells within the individual</td></tr><tr><td colspan="5">cleave the target mRNA. See Hammond et al., Nature 2000;</td><td colspan="2">with the one or more nucleic acids and wherein the cells either</td></tr><tr><td colspan="5">404:293-296; Reynolds et al., Nat Biotechnol 2004; 22:326</td><td colspan="2">express the one or more nucleic acids in a therapeutic manner</td></tr><tr><td colspan="5">330; Hammond et al., Science 2001; 293:1146-1150; and</td><td colspan="2">or the one or more nucleic acids inhibit expression of one or</td></tr><tr><td colspan="4">Bernstein et al., Nature 2001: 409:363-366.</td><td></td><td colspan="2">more proteins within the cells in a therapeutic manner.</td></tr><tr><td style="text-align: right">0005.</td><td colspan="4">Both viral and nonviral carriers have been used to</td><td style="text-align: right">00.10</td><td>Embodiments further include modulating gene</td></tr><tr><td colspan="5">carry interference RNA to their cytosolic mRNA target. See</td><td colspan="2">expression or cell function by using small RNA delivered by</td></tr><tr><td colspan="2">Simeoni et al., Nucleic Acids Res</td><td colspan="3">2003; 31:2717-2724.</td><td colspan="2">a composite of a rosette nanotube and small RNA. The result</td></tr></table></page>
<page number="27">
<table data-filename="Qian Chen - 2014 - NANOTUBES AS CARRIERS OF NUCLEIC ACIDS INTO CELLS , Patent App(2).pdf" data-page="27" data-table="1"><tr><td>US 2014/0171482 A1</td><td>Jun. 19, 2014</td></tr><tr><td>of the modulation of gene expression or cell function can be</td><td>and Zhang et al., Biomaterials 2009; 30(7): 1309-1320 each</td></tr><tr><td>therapeutic for particular indications.</td><td>of which are hereby incorporated by reference in their entire</td></tr><tr><td>0011 Further aspects include delivering small RNA into</td><td>ties for all purposes.</td></tr><tr><td>cells and the use of the delivered small RNA to regulate cell</td><td>0015 Rosette nanotubes of the present disclosure are very</td></tr><tr><td>signaling and function and influencing tissue or organ activi</td><td>stable in water and lack virus-related safety concerns and</td></tr><tr><td>ties. In particular, methods are provided of introducing Small</td><td>toxicity at amounts of about 1 g/ml. See Int. J. Nanomedi</td></tr><tr><td>RNA into cells using rosette nanotubes that advantageously</td><td>cine, 2008, 3(3):373-383. Small. 2008, 4(6): 817-823; and</td></tr><tr><td>do not require additional chemical modification of the com</td><td>Am. J. Physiol Lung Cell Mol. Physiol. 2005, November;</td></tr><tr><td>ponents of the delivery complex. The rosette nanotube and</td><td>289(5):L698-708 each of which are hereby incorporated by</td></tr><tr><td>small RNA complexes of the present disclosure are advanta</td><td>reference in their entireties.</td></tr><tr><td>geous in that they are nontoxic at administration levels and</td><td>0016. According to one aspect of the present disclosure,</td></tr><tr><td>they lack metals associated with known carriers.</td><td>methods are provided where the self-assembly of precursers</td></tr><tr><td></td><td>or modules incorporates the nucleic acid into or otherwise</td></tr><tr><td>0012. In particular, the methods include contacting a</td><td>complexes the nucleic acid with, the self-assembled rosette</td></tr><tr><td>transfection complex with one or more cells, where the trans</td><td>nanotube. According to another aspect, fully assembled</td></tr><tr><td>fection complex includes a rosette nanotube (“RNT) and a</td><td>rosette nanotubes can be incubated with one or more or a</td></tr><tr><td>nucleic acid such as DNA or RNA, for example siRNA or</td><td>plurality of nucleic acids and the one or more or plurality of</td></tr><tr><td>miRNA. Rosette nanotubes or RNTs include nanotubes</td><td>nucleic acids can complex with the fully assembled rosette</td></tr><tr><td>formed from modules having twin bases with a linker or TBL.</td><td>nanotube to form a composite. According to one further</td></tr><tr><td>Such rosette nanotubes may be referred to herein as “TBLs.”</td><td>aspect, the one or more or plurality of nucleic acids are joined</td></tr><tr><td>According to this aspect, the nucleic acid is delivered into the</td><td>to or bound to the self-assembled rosette nanotube through</td></tr><tr><td>cell. According to one aspect, the DNA is expressed by the</td><td>steric, ionic, Van der Waals, dispersion or other noncovalent</td></tr><tr><td>transfected cell. According to an additional aspect, the RNA</td><td>interactions to form a rosette nanotube and nucleic acid com</td></tr><tr><td>interacts with target RNA to regulate gene expression.</td><td>plex useful as a transfection agent and in some cases in the</td></tr><tr><td>According to one aspect, the DNA or RNA is released from</td><td>preparation of a pharmaceutical agent to be administered to</td></tr><tr><td>the rosette nanotube after entry into the cell. According to an</td><td>an individual. According to an additional further aspect, the</td></tr><tr><td>additional aspect, the DNA or RNA remains attached to,</td><td>one or more nucleic acids are covalently attached by methods</td></tr><tr><td>bound to, or complexed with or combined with the rosette</td><td>known to those of skill in the art to the rosette nanotube to</td></tr><tr><td>nanotube.</td><td>form a rosette nanotube and RNA complex useful as a trans</td></tr><tr><td>0013. According to one aspect, a transfection complex is</td><td>fection agent and in Some cases in the preparation of a phar</td></tr><tr><td>produced by combining modules of a self-assembled rosette</td><td>maceutical agent to be administered to an individual.</td></tr><tr><td>nanotube and one or more nucleic acids as DNA or RNA, for</td><td>0017. According to certain aspects, rosette nanotubes are</td></tr><tr><td>example siRNA or miRNA, in media where the modules</td><td>functionalized with small RNA to form a complex, for</td></tr><tr><td>self-assemble into a rosette nanotube which incorporates the</td><td>example RNA is bound to the rosette nanotube, the complex</td></tr><tr><td>one or more nucleic acids to form a complex of a rosette</td><td>is translocated into a cell, and the intracellular small RNA is</td></tr><tr><td>nanotube and the one or more nucleic acids. According to an</td><td>present within the cell in an amount Sufficient for gene silenc</td></tr><tr><td>additional aspect, a transfection complex is produced by com</td><td>ing resulting in the inhibition of the production of target</td></tr><tr><td>bining a self-assembled rosette nanotube and one or more</td><td>proteins. In this aspect, the rosette nanotube is a delivery</td></tr><tr><td>nucleic acids such as DNA or RNA, for example siRNA or</td><td>vehicle or carrier for the small RNA into a cell for RNA</td></tr><tr><td>miRNA, in media whereupon the one or more nucleic acids</td><td>interference purposes.</td></tr><tr><td>are incorporated into the rosette nanotube to form a complex</td><td>0018. According to an alternate aspect, nanotubes are</td></tr><tr><td>of a rosette nanotube and one or more nucleic acids. The</td><td>functionalized with desired DNA to form a complex, the</td></tr><tr><td>transfection complex may then be contacted to cells where</td><td>complex is translocated into a cell, and the desired DNA is</td></tr><tr><td>upon the transfection complex enters the cells. Without wish</td><td>released from the complex and incorporated into the DNA of</td></tr><tr><td>ing to be bound by scientific theory, it is believes that the</td><td>the cell. The desired DNA is then expressed by the cell. In this</td></tr><tr><td>complex may enter cells by endocytosis. According to certain</td><td>aspect, the rosette nanotube is a delivery vehicle or carrier for</td></tr><tr><td>embodiments, the cells may be transformed cells, recombi</td><td>the desired DNA into a cell for expression purposes. One of</td></tr><tr><td>nant cells, malignant cells, or cells from primary cell lines.</td><td>skill in the art will readily understand based on the present</td></tr><tr><td>The transfection method may be performed on cells in vitro or</td><td>disclosure that target DNA, such as a gene to be expressed,</td></tr><tr><td>1 V1VO.</td><td>can be transfected into a cell using the delivery vehicles and</td></tr><tr><td>0014. The modules may be any of those known to persons</td><td>techniques described herein or readily available to those of</td></tr><tr><td>of ordinary skill in the art such as GMC motifs, unmodified or</td><td>skill in the art, and thereafter expressed using methods known</td></tr><tr><td>modified to include moieties or sidechains, which self-as</td><td>to those of skill in the art.</td></tr><tr><td>semble into helical rosette nanotubes. According to one</td><td>0019 Embodiments of the present invention are still fur</td></tr><tr><td>embodiment, modules are placed into an aqueous medium</td><td>ther directed to compositions including rosette nanotube?</td></tr><tr><td>where they self assemble into a Substructure such as a ring</td><td>nucleic acid complexes used as a vehicle for the delivery of</td></tr><tr><td>structure, such as a rosette, and the ring structures then self</td><td>the nucleic acid. Such as RNA into aparticular cell. According</td></tr><tr><td>assemble by stacking one on top of another to form a tubular</td><td>to certain embodiments, the rosette nanotube and RNA com</td></tr><tr><td>structure, commonly referred to as a nanotube. Such modules,</td><td>plexes are mixed with a pharmaceutically acceptable excipi</td></tr><tr><td>Substructures and nanometer scale molecular structures and</td><td>ent or delivery vehicle and then delivered to the desired loca</td></tr><tr><td>their self-assembly is described in U.S. Pat. No. 6,696.565,</td><td>tion and in a manner to transfect cells with the RNA, for</td></tr><tr><td>Fenniri et al., J. Am. Cheni. Soc. 2001, 123, 3854-3855,</td><td>example, for therapeutic purposes through the inhibition or</td></tr><tr><td>Moralez et al., J. Am. Chem. Soc., 2005, 127, 8307-8309, Fine</td><td>alteration of the expression of a target gene. In addition,</td></tr><tr><td>et al., International Journal of Nanomedicine 2009:49.1-97;</td><td>transfection kits are provided that include the rosette nano</td></tr></table></page>
<page number="28">
<table data-filename="Qian Chen - 2014 - NANOTUBES AS CARRIERS OF NUCLEIC ACIDS INTO CELLS , Patent App(2).pdf" data-page="28" data-table="1"><tr><td colspan="2">US 2014/0171482 A1</td><td>Jun. 19, 2014</td></tr><tr><td colspan="2">tubes of the present invention for complexing with one or</td><td>(A and C) and fluorescent (B and D) pictures of ADTC5</td></tr><tr><td colspan="2">more desired nucleic acids using the methods described</td><td>chondrocytes cultured with only GAPDH molecular beacons</td></tr><tr><td colspan="2">herein pursuant to instructions and optional reagents pro</td><td>(A and B) or with RNT/GAPDH molecular beacons (C and</td></tr><tr><td colspan="2">vided in the kit to form a transfection reagent for transfection</td><td>D).</td></tr><tr><td colspan="2">of a desired cell.</td><td>0033 FIG. 14 depicts images of internalized RNT/</td></tr><tr><td></td><td></td><td>GAPDH molecular beacons located in the cytoplasm. Light</td></tr><tr><td></td><td>BRIEF DESCRIPTION OF THE DRAWINGS</td><td>(A and C) and fluorescent (B and D) pictures of primary</td></tr><tr><td style="text-align: right">0020</td><td>FIG. 1 shows the structure of an exemplary module</td><td>chicken chondrocytes cultured with only GAPDH molecular</td></tr><tr><td colspan="2">used to form a rosette nanotube. Shown in schematic form is</td><td>beacons (A and B) or with RNT/GAPDH molecular beacons</td></tr><tr><td colspan="2">a rosette nanotube and also shown is an image of rosette</td><td>(C and D).</td></tr><tr><td colspan="2">nanotubes of the present disclosure.</td><td>0034 FIG. 15 depicts images of internalized RNT/</td></tr><tr><td style="text-align: right">0021</td><td>FIG. 2 is a graphical comparison of RNT (rosette</td><td>miR365 molecular beacons located in the cytoplasm. Light</td></tr><tr><td colspan="2">nanotubes), RNA, RNT/RNA composites (Left); RNT/RNA</td><td>(A and C) and fluorescent (B and D) pictures of mouse chon</td></tr><tr><td colspan="2">composites and the sum of absorbance RNTs and RNA</td><td>drocytes cultured with only GAPDH molecular beacons (A</td></tr><tr><td colspan="2">(Right) in UV-vis spectroscopy.</td><td>and B) or with RNT/GAPDH molecular beacons (C and D).</td></tr><tr><td style="text-align: right">0022</td><td>FIG. 3 is a graphical comparison of RNT, RNA,</td><td>0035 FIG. 16 depicts images of internalized RNT/green</td></tr><tr><td colspan="2">RNT/RNA composites (Left); RNT/RNA composites and the</td><td>fluorescence labeled siRNA located in the cytoplasm. Light</td></tr><tr><td colspan="2">sum of absorbance RNTs and RNA (Right in CD spectros</td><td>(A and C) and fluorescent (B and D) pictures of primary</td></tr><tr><td>copy.</td><td></td><td>human chondrocytes cultured with only siRNA (A and B) or</td></tr><tr><td style="text-align: right">0023</td><td>FIG. 4 is a graphical comparison of RNT denatur</td><td>with RNT/siRNA (C and D).</td></tr><tr><td colspan="2">ation curve (Left) and RNT/RNA composites denaturation</td><td>0036 FIG. 17 depicts images of internalized RNT/green</td></tr><tr><td colspan="2">curve (Right) with the first derivative of such curve demon</td><td>fluorescence labeled siRNA located in the cytoplasm. Light</td></tr><tr><td colspan="2">strating the denaturation temperature of RNT/RNA compos</td><td>(A and C) and fluorescent (B and D) pictures of primary pig</td></tr><tr><td>ites.</td><td></td><td>chondrocytes cultured with only siRNA (A and B) or with</td></tr><tr><td style="text-align: right">0024</td><td>FIG. 5 are images of the electrophoresis of RNTs</td><td>RNT/siRNA (C and D).</td></tr><tr><td colspan="2">and RNT/RNA composites.</td><td>0037 FIG. 18 depicts images of internalized RNT/green</td></tr><tr><td style="text-align: right">0025</td><td>FIG. 6 is an atomic force microscopic image of</td><td>fluorescence labeled siRNA located in the cytoplasm. Light</td></tr><tr><td colspan="2">rosette nanotubes only.</td><td>(A and C) and fluorescent (Band D) pictures of human breast</td></tr><tr><td style="text-align: right">0026</td><td>FIG. 7A is an atomic force microscopic image of a</td><td>cancer cell line (MCF7) cultured with only siRNA (A and B)</td></tr><tr><td colspan="2">complex of rosette nanotubes and RNA. FIG. 7B is a trans</td><td>or with RNT/siRNA (C and D).</td></tr><tr><td colspan="2">mission electron microscope image of RNTs. FIG. 7C is a</td><td>0038 FIG. 19 depicts images of internalized RNT/green</td></tr><tr><td colspan="2">transmission electron microscope image of a complex of</td><td>fluorescence labeled siRNA located in the cytoplasm. Light</td></tr><tr><td colspan="2">RNTS and RNA.</td><td>(A and C) and fluorescent (Band D) pictures of rat astrocyte</td></tr><tr><td style="text-align: right">0027</td><td>FIG. 8 are images of fluorescence microscopy of the</td><td>cell line (CRL2005) cultured with only siRNA (A and B) or</td></tr><tr><td colspan="2">treated cells revealing internalized RNT/SiRNA. Light (A</td><td>with RNT/siRNA (C and D).</td></tr><tr><td colspan="2">and C) and fluorescent (B and D) pictures of chondrocytes</td><td>0039 FIG. 20 depicts images of internalized RNT/green</td></tr><tr><td colspan="2">cultured with only FITC-RNA (A and B) or with FITC-RNA</td><td>fluorescence labeled siRNA located in the cytoplasm. Light</td></tr><tr><td colspan="2">RNTs (C and D).</td><td>(A and C) and fluorescent (B and D) pictures of human</td></tr><tr><td style="text-align: right">0028</td><td>FIG.9 depicts images of internalized RNT/SiRNA</td><td>chondrosarcoma cells cultured with only siRNA (A and B) or</td></tr><tr><td colspan="2">located in the cytoplasm. Confocal images of FITC-SiRNA</td><td></td></tr><tr><td colspan="2">(A) and HDAC4 (B), DAP1 (C) as well as overlay (D). FIG.</td><td>with RNT/siRNA (C and D).</td></tr><tr><td colspan="2">9(E) is a 2D confocal image of FITC-SiRNA internalized by</td><td>0040 FIG. 21 depicts images of internalized RNT/green</td></tr><tr><td colspan="2">cells. FIG. 9(F) is a 3D confocal image of FITC-SiRNA</td><td>fluorescence labeled siRNA located in the cytoplasm. Light</td></tr><tr><td colspan="2">internalized by cells.</td><td>(A and C) and fluorescent (B and D) pictures of mouse mac</td></tr><tr><td style="text-align: right">0029</td><td>FIG. 10 depicts images showing that siRNA deliv</td><td>rophage cell line (RAW264.7) cultured with only siRNA (A</td></tr><tr><td colspan="2">ered into chondrocytes by RNT induced the RNAi response.</td><td>and B) or with RNT/siRNA (C and D).</td></tr><tr><td colspan="2">HDAC4 mRNA level was determined by the real-time PCR</td><td>0041 FIG. 22 depicts images of internalized RNT/green</td></tr><tr><td colspan="2">(A) and HDAC4 protein expression by western blot (B) and</td><td>fluorescence labeled siRNA located in the cytoplasm. Light</td></tr><tr><td colspan="2">quantitative analysis of HDAC4 protein expression (C).</td><td>(A and C) and fluorescent (B and D) pictures of primary</td></tr><tr><td colspan="2">*P&lt;0.05 compared with the consiRNA.</td><td>chicken liver cells cultured with only siRNA (A and B) or</td></tr><tr><td style="text-align: right">0030</td><td>FIG. 11 is a graph demonstrating that miRNA was</td><td>with RNT/siRNA (C and D).</td></tr><tr><td colspan="2">functionally delivered into chondrocytes by RNTs to induce</td><td>0042 FIG. 23 is the quantitative analysis of the fluores</td></tr><tr><td colspan="2">RNAi response with an increase of miRNA 365 expression</td><td>cence molecular tomography in the mouse. *P&lt;0.05 com</td></tr><tr><td colspan="2">level. *P&lt;0.05 compared with the controls.</td><td>pared with the control group (Beacon only) at the respective</td></tr><tr><td style="text-align: right">0031</td><td>FIG. 12(A) is a graph demonstrating that miRNA</td><td>time point.</td></tr><tr><td colspan="2">inhibitor was functionally delivered into chondrocytes by</td><td>0043 FIG. 24 is flow cytometry data showing the fluores</td></tr><tr><td colspan="2">RNTs to induce RNAi response with a decrease of miRNA</td><td>cence of cells cultured with siRNA only, RNT/RNA and</td></tr><tr><td colspan="2">365 expression level. FIG. 12(B) a graph demonstrating that</td><td>Lipofectamine/RNA.</td></tr><tr><td colspan="2">miRNA inhibitor was functionally delivered into chondro</td><td>0044 FIG. 25 is a graph comparing the ability of lipo</td></tr><tr><td colspan="2">cytes by TBLs to induce RNAi response with a decrease of</td><td>fectamine and RNTs to deliver GAPDH molecular beacons</td></tr><tr><td colspan="2">miRNA 365 expression level. *P&lt;0.05 compared with the</td><td>into cells. Light (A and C) and fluorescent (B and D) pictures</td></tr><tr><td colspan="2">controls (scrambled RNA).</td><td>of primary mouse chondrocytes cultured with lipofectamine?</td></tr><tr><td style="text-align: right">0032</td><td>FIG. 13 depicts images of internalized RNT/</td><td>GAPDH molecular beacons (A and B) or with RNT/GAPDH</td></tr><tr><td colspan="2">GAPDH molecular beacons located in the cytoplasm. Light</td><td>molecular beacons (C and D).</td></tr></table></page>
<page number="29">
<table data-filename="Qian Chen - 2014 - NANOTUBES AS CARRIERS OF NUCLEIC ACIDS INTO CELLS , Patent App(2).pdf" data-page="29" data-table="1"><tr><td colspan="3">US 2014/0171482 A1</td><td></td><td></td><td></td><td></td><td></td><td>Jun. 19, 2014</td></tr><tr><td style="text-align: right">0045</td><td colspan="4">FIG. 26 a graph comparing the ability of lipo</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="5">fectamine, TBLs and RNTs to deliver miR365 mimic into</td><td></td><td></td><td>O</td><td>NH2</td></tr><tr><td colspan="5">cells and to influence expression of downstream gene. *P&lt;0.</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="5">05 compared with the controls and lipofectamine/miR365</td><td></td><td>HN</td><td></td><td>NN</td></tr><tr><td colspan="5">mimic. **P&lt;0.05 compared with the controls.</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">ls</td><td>1s</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>HN</td><td>X</td><td>O</td></tr><tr><td></td><td colspan="4">DETAILED DESCRIPTION OF CERTAIN</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td colspan="4">EXEMPLARY EMBODIMENTS</td><td></td><td>R</td><td></td><td>(CH2)n</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Y</td></tr><tr><td style="text-align: right">0046.</td><td colspan="4">The aspects, advantages and other features of the</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="5">disclosure will become apparent in view of the following</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="5">detailed description, which discloses various non-limiting</td><td style="text-align: right">0049.</td><td colspan="3">An exemplary module within the scope of formula I</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="4">is shown in FIG. 1 along with a schematic representation of a</td></tr><tr><td colspan="5">embodiments of the disclosure. In describing embodiments</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="5">of the present disclosure, specific terminology is employed</td><td colspan="4">nanotube and an image of nanotubes formed from the exem</td></tr><tr><td colspan="5">for the sake of clarity. However, the disclosure is not intended</td><td colspan="4">plary module.0050 Alternative linker groups R can join the Y group to</td></tr><tr><td colspan="5">to be limited to the specific terminology so selected. It is to be</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="5">understood that each specific element includes all technical</td><td colspan="4">the carbon of the (CH) group or the Natom either by theamino group or the carboxyl group of the amino acid or</td></tr><tr><td colspan="5">equivalents that operate in a similar manner to accomplish a</td><td colspan="2">polypeptide.</td><td></td><td></td></tr><tr><td colspan="5">similar purpose. Additionally, all of the citations herein are</td><td style="text-align: right">0051</td><td colspan="3">Alternative Linker moieties within the scope of the</td></tr><tr><td colspan="5">incorporated by reference in their entirety.</td><td colspan="4">present disclosure include NH' and the following</td></tr><tr><td style="text-align: right">0047</td><td colspan="4">Embodiments of the present disclosure involve</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="5">transfecting cells with one or more nucleic acids, such as</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="5">DNA or RNA. RNA can be small RNA including siRNA and</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="5">miRNA. In particular, disclosed herein are novel siRNA</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="5">transport complexes, comprising an unexpectedly advanta</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="5">geous transport vehicle. Methods of the present invention</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="5">include contacting a transfection complex described herein</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="5">with one or more cells, where the transfection complex</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="5">includes a rosette nanotube and one or more nucleic acids</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="5">such as DNA and RNA, for example siRNA. The rosette</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="5">nanotube is a carrier that is formed from self-assembled mod</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="5">ules as described below and those modules recognized in the</td><td></td><td></td><td></td><td></td></tr><tr><td>art.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">0048</td><td colspan="4">Modules according to the present disclosure include</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="3">compounds of Formula I below:</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>O</td><td>NH2</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>HN</td><td colspan="2">NN</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>ls</td><td colspan="2">1s</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>HN</td><td>X</td><td>N</td><td>O</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>R</td><td></td><td>R2</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Y</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="5">wherein X is CH or nitrogen; n is an integer of 1, 2, 3, or 4:</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="5">R is hydrogen or a linker group for example (CH), or other</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="5">linker groups described herein;Y is absent when R is hydro</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="5">gen or is an amino acid or polypeptide having an amino group</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="5">covalently bound to an O-carbon of the amino acid and the</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="5">amino group is covalently bound to the linker group R, and</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="5">R is hydrogen or an aliphatic moiety, such as alkyl, straight</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="5">or branched chain, Saturated or unsaturated; and salts thereof.</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="5">Preferably R is C to Coalkyl, C to Cs alkyl, C to C alkyl,</td><td style="text-align: right">0.052</td><td colspan="3">Compounds of Formula I can be prepared by the</td></tr><tr><td colspan="5">or methyl. Compounds within the scope of the invention</td><td colspan="4">methods described in U.S. Pat. No. 6,696.565 hereby incor</td></tr><tr><td colspan="5">include those where the Y group can be connected to the</td><td colspan="4">porated by reference herein in its entirety alone or combined</td></tr><tr><td colspan="5">linker group either by the amino group or the carboxyl group</td><td colspan="4">with methods known to those of skill in the art.</td></tr><tr><td colspan="5">of the amino acid or polypeptide. An exemplary linker group</td><td style="text-align: right">0053</td><td colspan="3">Modules according to the present disclosure also</td></tr><tr><td colspan="3">is shown in the formula below.</td><td></td><td></td><td colspan="4">include compounds of Formula II below:</td></tr></table></page>
<page number="30">
<table data-filename="Qian Chen - 2014 - NANOTUBES AS CARRIERS OF NUCLEIC ACIDS INTO CELLS , Patent App(2).pdf" data-page="30" data-table="1"><tr><td colspan="5">US 2014/0171482 A1</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">Jun. 19, 2014</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">-continued</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>O</td><td>NH2</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>HN</td><td></td><td></td><td colspan="2">NN</td><td></td><td></td><td></td><td></td><td>A-</td><td></td><td>Me</td><td colspan="2">x</td></tr><tr><td></td><td colspan="2">ls</td><td></td><td></td><td style="text-align: right" colspan="2">1.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>I</td><td></td><td>X</td><td>N</td><td></td><td>O</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>R</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>O</td><td></td><td></td><td></td><td></td><td>O</td><td></td><td></td></tr><tr><td></td><td></td><td>R</td><td colspan="3">-+H'Nn'-1a</td><td>N</td><td>l</td><td></td><td>N</td><td></td><td></td><td></td><td>NHGE)</td><td></td></tr><tr><td></td><td>Y</td><td>Y</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>N</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>h</td><td colspan="2">N</td><td></td><td>NH2</td><td></td><td></td><td>ls</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>O</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>R</td><td>NN</td><td></td><td>N</td><td></td><td></td><td>O</td><td></td><td></td><td></td><td></td><td>St.</td></tr><tr><td></td><td></td><td></td><td></td><td>H</td><td></td><td>H</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>N</td><td></td><td></td></tr><tr><td colspan="5">wherein X is CH or nitrogen; R</td><td colspan="5">is hydrogen or a linker group</td><td></td><td></td><td>e H3</td><td></td><td></td></tr><tr><td colspan="10">for example (CH), where n is an integer of 1, 2, 3, or 4 or</td><td></td><td></td><td>O</td><td></td><td></td></tr><tr><td colspan="10">(CH2)CO other linker groups described herein; Y is absent</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="10">when R is hydrogen or is an amino acid or polypeptide</td><td></td><td>--~~</td><td></td><td style="text-align: right">21</td><td></td></tr><tr><td colspan="10">having an amino group covalently bound to an O-carbon of</td><td></td><td></td><td>H</td><td></td><td></td></tr><tr><td colspan="10">the amino acid and the amino group is covalently bound to the</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="4">linker group R, and R</td><td colspan="6">is hydrogen or an aliphatic moiety,</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="10">Such alkyl, straight or branched chain, Saturated or unsatur</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="7">ated; and salts thereof. Preferably R</td><td colspan="3">is C to Coalkyl, C to</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="10">Cs alkyl, C to C alkyl, or methyl. An exemplary linkergroup</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="5">is shown in the formula below.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">0055</td><td colspan="4">According to certain aspects of the present disclo</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="5">sure, the structure of Formula II is referred to as a twin base</td></tr><tr><td></td><td></td><td></td><td>O</td><td></td><td>NH2</td><td></td><td></td><td></td><td></td><td colspan="5">with a linker (TBL) or twin base linkers insofar as two similar</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="5">double ring structures are present as shown in Formula II and</td></tr><tr><td></td><td></td><td>HN</td><td></td><td></td><td colspan="2">NN</td><td></td><td></td><td></td><td colspan="5">are linked to an amino acid or polypeptide. However, it is to be</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="5">understood that the two double ring structures need not be</td></tr><tr><td></td><td></td><td colspan="2">ls</td><td></td><td></td><td colspan="2">1s</td><td></td><td></td><td colspan="4">identical insofar as they may have different X and R</td><td>groups.</td></tr><tr><td></td><td>I</td><td></td><td>X</td><td></td><td>N</td><td></td><td>O</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">0056.</td><td colspan="4">The term “amino acid' is inclusive of the 20 com</td></tr><tr><td></td><td></td><td>R</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="5">mon amino acids, as well as “nonstandard amino acids.” for</td></tr><tr><td></td><td>O</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>O</td><td colspan="5">example, D-amino acids and chemically (or biologically)</td></tr><tr><td></td><td></td><td></td><td></td><td>+HN</td><td></td><td></td><td></td><td></td><td>l</td><td colspan="3">produced derivatives of “common</td><td colspan="2">amino acids, including</td></tr><tr><td></td><td style="text-align: right" colspan="3">,---</td><td></td><td colspan="2">N-1 n</td><td></td><td></td><td>h</td><td colspan="2">for example, 3-amino acids.</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">0057</td><td colspan="4">Accordingly, amino acids according to the present</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>h</td><td>N</td><td></td><td>NH2</td><td colspan="5">disclosure include the commonly known amino acids such as</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="5">glycine (Gly, G), alanine (Ala., A), Valine (Val, V), leucine</td></tr><tr><td></td><td></td><td></td><td></td><td>R</td><td>NN</td><td></td><td>N</td><td></td><td>O</td><td colspan="5">(Leu, L), isoleucine (Ile, I), proline (Pro, P), hydroxyproline,</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>H</td><td></td><td>H</td><td></td><td></td><td colspan="5">phenylalanine (Phe, F), tyrosine (Tyr,Y), tryptophan (Trp, W)</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="5">cysteine (Cys, C), methionine (Met, M) serine (Ser, S),</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="5">o-phosphoserine, threonine (Thr, T), lysine (LyS, K), arginine</td></tr><tr><td style="text-align: right">0054</td><td colspan="9">Compounds within the scope of the present disclo</td><td colspan="5">(Arg, R), histidine (H is, H), aspartate (Asp, D), glutamate</td></tr><tr><td colspan="10">sure include those where the Y group can be connected to the</td><td>(Glu,</td><td colspan="4">E), Y-carboxyglutamate, asparagine (ASn, N),</td></tr><tr><td colspan="10">linker group either by the amino group or the carboxyl group</td><td colspan="5">glutamine (Gln, Q) and the like. Amino acids also include</td></tr><tr><td colspan="10">of the amino acid or polypeptide. Alternative linker groups R.</td><td colspan="5">Stereoisomers thereof and compounds structurally similar to</td></tr><tr><td colspan="3">connecting the NH</td><td colspan="6">group and the Y group include</td><td></td><td>the amino acids or</td><td colspan="2">modifications</td><td>or derivatives</td><td>thereof.</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="5">Exemplary amino acids within the scope of the present dis</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="5">closure include lysine, arginine, serine, glycine, aspartate and</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>the like.</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>GE)</td><td></td><td></td><td></td><td></td><td></td><td>GE)</td><td style="text-align: right">0058.</td><td colspan="4">The term "peptide' is inclusive of both straight and</td></tr><tr><td></td><td></td><td></td><td>NH</td><td></td><td></td><td></td><td></td><td></td><td>NH</td><td colspan="5">branched amino acid chains, as well as cyclic amino acid</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="5">chains, which comprise at least 2 amino acid residues. The</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>GE)</td><td colspan="5">terms “peptide' and “polypeptide' are used interchangeably</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>NH</td><td></td><td colspan="5">herein. Accordingly, polypeptides according to the present</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="5">disclosure include two or more amino acids covalently linked</td></tr></table></page>
<page number="31">
<table data-filename="Qian Chen - 2014 - NANOTUBES AS CARRIERS OF NUCLEIC ACIDS INTO CELLS , Patent App(2).pdf" data-page="31" data-table="1"><tr><td>US 2014/0171482 A1</td><td>Jun. 19, 2014</td></tr><tr><td>together. According to one aspect, the two or more amino</td><td>stacked in any desired sequence to form nanotubular struc</td></tr><tr><td>acids are covalently linked together at least in part by one or</td><td>tures of the present invention. Utilizing this aspect of the</td></tr><tr><td>more peptide bonds.</td><td>present invention, a wide variety of structurally different</td></tr><tr><td>0059. According to aspects of the present disclosure, mod</td><td>modules (i.e. molecules) can be synthesized and self-as</td></tr><tr><td>ules (compounds) according to Formula I and Formula II</td><td>sembled into Supermacrocycles and then nanotubular struc</td></tr><tr><td>self-assemble into Substructures also called Supermacro</td><td>tures according to methods of the present invention.</td></tr><tr><td>cycles which themselves will self-assemble into nanometer</td><td>0062 According to certain aspects of the present disclo</td></tr><tr><td>scale architectures or structures Such as discrete nanotubular</td><td></td></tr><tr><td>assemblies in water or aqueous solutions. Supermacrocycles</td><td>Sure, nanotubes range in lengths between about 1 nm and<br/>about 999 microns, about 1 nm to about 500 nm, about 10 nm.</td></tr><tr><td>are defined herein as being a number of organic molecules</td><td>to about 300 nm, or about 20 nm to about 100 nm. The</td></tr><tr><td>covalently or noncovalently bound together so as to form a</td><td>nanotubes range in diameters between about 1 angstrom and</td></tr><tr><td>ring structure. For example, compounds of Formula I will</td><td>about 100 nm, about 1 nm to about 30 nm, or from about 3 nm.</td></tr><tr><td>self-assemble into a 6-merring structure, sometimes referred</td><td>to about 15 nm. The openings or inner diameters through the</td></tr><tr><td>to as a rosette. The process of forming nanotubes with the</td><td>nanotubes range in diameters between about 1 angstrom and</td></tr><tr><td>modules of the present disclosure is hierarchical. In particu</td><td>about 100 nm, about 1 nm to about 30 nm, or from about 3 nm.</td></tr><tr><td>lar, the modules of the present invention first self-assemble</td><td>to about 15 nm. According to certain embodiments, the open</td></tr><tr><td>into Supermacrocycles, and then the Supermacrocycles self</td><td>ing or inner diameter through the nanotube has a diameter of</td></tr><tr><td>assembly into nanotubes. Such self-assembly is described in</td><td>about 1 nm. According to certain embodiments, the nano</td></tr><tr><td>U.S. Pat. No. 6,696.565. For the compounds of Formula II</td><td>tubes formed from the twin base linkers of formula II have a</td></tr><tr><td>referred to as twin base linkers, the compounds will also</td><td>different opening or inner diameter compared to nanotubes</td></tr><tr><td>assemble into a 6-merring structure. However, a single Super</td><td>formed from the compounds of formula I. This aspect which</td></tr><tr><td>macrocycle formed will include two base layers owing to the</td><td>allows for the incorporation into the nanotube of different</td></tr><tr><td>presence of the two bases in each of the compound of Formula</td><td>sizes of agents, such as nucleic acids.</td></tr><tr><td>II.</td><td></td></tr><tr><td>0060 According to preferred aspects of the present dis</td><td>0063. According to certain preferred aspects of the present</td></tr><tr><td>closure, the compounds of Formula and Formula II include</td><td>invention, a nanotube is prepared from single base ring struc</td></tr><tr><td>low molecular weight synthetic DNA base analogues referred</td><td>tures and twin base ring structures in any desired order. The</td></tr><tr><td>to by the nomenclature CM G. See Fennirietal, J. Am. Chem.</td><td>nanotube can have one or more single base ring structures and</td></tr><tr><td>Soc. 2001, 123,3854-3855. The CAG moiety, referred to as</td><td>one or more twin base ring structures. Likewise, a nanotube</td></tr><tr><td>a single CM G motif, possess the Watson-Crick donor-donor</td><td>within the scope of the present invention can include a plu</td></tr><tr><td>acceptor of guanine and the acceptor-acceptor-donor of</td><td>rality of single base ring structures formed from compounds</td></tr><tr><td>cytosine and undergoes a self-assembly process, fueled by an</td><td>of Formula I and a plurality of twin base ring structures</td></tr><tr><td>array of hydrogen bonds, to produce a six-membered Super</td><td>formed from compounds of Formula II stacked together, i.e.</td></tr><tr><td>macrocycle or rosette. Stacking of these rosettes produced a</td><td>one next to the other via hydrogen bonding, to form the</td></tr><tr><td>nanotube of very high aspect ratio. Compounds within the</td><td>nanotube.</td></tr><tr><td>scope of the present invention include a twin G M C motif</td><td>0064. As may be used herein, the terms “nucleic acid.”</td></tr><tr><td>denoted as (CMG). Like the single CMG motif, the twin C</td><td>“nucleic acid molecule.” “nucleic acid oligomer.” “oligo</td></tr><tr><td>m G motif (CMG), also possesses the Watson-Crick donor</td><td>nucleotide.” “nucleic acid sequence.” “nucleic acid frag</td></tr><tr><td>donor-acceptor of guanine and the acceptor-acceptor-donor</td><td>ment” and “polynucleotide' are used interchangeably and are</td></tr><tr><td>of cytosine and undergoes a self assembly process, fueled by</td><td>intended to include, but are not limited to, a polymeric form of</td></tr><tr><td>an array of hydrogen bonds, to produce a six-membered</td><td>nucleotides covalently linked together that may have various</td></tr><tr><td>Supermacrocycle or ring structure (rosette) of twin configu</td><td>lengths, either deoxyribonucleotides or ribonucleotides, or</td></tr><tr><td>ration. Stacking of these twin rosettes produces a nanotube of</td><td>analogs, derivatives or modifications thereof. Different poly</td></tr><tr><td>very high aspect ratio and higher stability.</td><td>nucleotides may have different three-dimensional structures,</td></tr><tr><td>0061. It should be understood that the above described</td><td>and may perform various functions, known or unknown.</td></tr><tr><td>Formula I and Formula II demonstrate that electrostatic,</td><td>Non-limiting examples of polynucleotides include a gene, a</td></tr><tr><td>stacking and hydrophobic interactions can be effectively</td><td>gene fragment, an exon, an intron, intergenic DNA (includ</td></tr><tr><td>orchestrated by hydrogen bonds to direct the hierarchical</td><td>ing, without limitation, heterochromatic DNA), messenger</td></tr><tr><td>assembly and organization of helical nanotubular architec</td><td>RNA (mRNA), transfer RNA, ribosomal RNA, a ribozyme,</td></tr><tr><td>tures in an aqueous milieu. Helical nanotubular architectures</td><td>cDNA, a recombinant polynucleotide, a branched polynucle</td></tr><tr><td>within the scope of the present invention include those</td><td>otide, a plasmid, a vector, isolated DNA of a sequence, iso</td></tr><tr><td>formed entirely from compounds of Formula I. Helical nano</td><td>lated RNA of a sequence, a nucleic acid probe, and a primer.</td></tr><tr><td>tubular architectures within the scope of the present invention</td><td>Polynucleotides useful in the methods of the invention may</td></tr><tr><td>include those formed entirely from compounds of Formula II.</td><td>comprise natural nucleic acid sequences and variants thereof,</td></tr><tr><td>Further, helical nanotubular architectures within the scope of</td><td>artificial nucleic acid sequences, or a combination of Such</td></tr><tr><td>the present invention include those formed from one or more</td><td>sequences. As used herein, one of skill in the art will under</td></tr><tr><td>of the compounds of Formula I and one or more of the com</td><td>stand that the term “nucleic acid probe' includes probes</td></tr><tr><td>pounds of Formula II. For example, a Supermacrocycle ring</td><td>known as molecular beacons which include synthetic oligo</td></tr><tr><td>Substructure having particular amino acid or polypeptide side</td><td>nucleotide hybridization probes that can report the presence</td></tr><tr><td>chains formed from the compounds of Formula I can be</td><td>of specific nucleic acids in homogenous solutions or in cells.</td></tr><tr><td>stacked with a Supermacrocycle ring Substructure having par</td><td>Species of molecular beacons include hairpin shaped mol</td></tr><tr><td>ticular amino acid or polypeptide side chains formed from</td><td>ecules with an internally quenched fluorophore whose fluo</td></tr><tr><td>compounds of Formula II. The rosette substructures formed</td><td>rescence is restored when they bind to a target nucleic acid</td></tr><tr><td>from the compounds of Formula I and Formula II can be</td><td>sequence. Technically, molecular beacons can be designed to</td></tr></table></page>
<page number="32">
<table data-filename="Qian Chen - 2014 - NANOTUBES AS CARRIERS OF NUCLEIC ACIDS INTO CELLS , Patent App(2).pdf" data-page="32" data-table="1"><tr><td>US 2014/0171482 A1</td><td>Jun. 19, 2014</td></tr><tr><td>target any gene and can be linked with fluorescent molecules</td><td>complexed with rosette nanotubes using the methods</td></tr><tr><td>of different fluorescence wavelengths.</td><td>described herein and that an exhaustive listing of publicly</td></tr><tr><td>0065. A polynucleotide is typically composed of, a spe</td><td>known siRNA sequences need not be provided herein.</td></tr><tr><td>cific sequence of four nucleotide bases: adenine (A): cytosine</td><td>0068 According to additional aspects, DNA includes any</td></tr><tr><td>(C); guanine (G); and thymine (T) (uracil (U) for thymine (T)</td><td>DNA desired to be expressed by a cell. DNA includes genes</td></tr><tr><td>when the polynucleotide is RNA). Thus, the term “polynucle</td><td>having known functions and expressing known proteins.</td></tr><tr><td>otide sequence' is the alphabetical representation of a poly</td><td>Likewise, DNA suitable for transfecting a cell will be appar</td></tr><tr><td>nucleotide molecule; alternatively, the term may be applied to</td><td>ent to those of skill in the art of transfection and gene expres</td></tr><tr><td>the polynucleotide molecule itself. This alphabetical repre</td><td>S1O.</td></tr><tr><td>sentation can be input into databases in a computer having a</td><td>0069. The present disclosure is directed to methods of</td></tr><tr><td>central processing unit and used for bioinformatics applica</td><td>forming a transfection complex, for example, by mixing one</td></tr><tr><td>tions such as functional genomics and homology searching.</td><td>or more nucleic acids with fully formed rosette nanotubes or</td></tr><tr><td>Polynucleotides may optionally include one or more non</td><td>modules that self-assemble into rosette nanotubes, such as the</td></tr><tr><td>standard nucleotide(s), nucleotide analog(s) and/or modified</td><td>compounds of formula I or formula II. According to one</td></tr><tr><td>nucleotides.</td><td>aspect, fully formed rosette nanotubes in the form of a powder</td></tr><tr><td>0066 Examples of modified nucleotides include, but are</td><td>is dissolved in water and heated to boiling. The solution is</td></tr><tr><td>not limited to 5-fluorouracil, 5-bromouracil, 5-chlorouracil,</td><td>then cooled to room temperature. One or more nucleic acids</td></tr><tr><td>5-iodouracil, hypoxanthine, Xantine, 4-acetylcytosine,</td><td>in the form of a solution is then added to the solution of</td></tr><tr><td>5-(carboxyhydroxylmethyl)uracil, 5-carboxymethylami</td><td>nanotubes at a suitable temperature and for a suitable period</td></tr><tr><td>nomethyl-2-thiouridine, 5-carboxymethylaminomethylu</td><td>of time until a complex of the nanotube and one or more</td></tr><tr><td>racil, dihydrouracil, beta-D-galactosylqueosine, inosine,</td><td>nucleic acids forms. Suitable ratios of the nucleic acid to</td></tr><tr><td>N6-isopentenyladenine, 1-methylguanine, 1-methylinosine,</td><td>nanotube include about 0.01:1 (wit/wt) to about 1:0.1 (wt/wt).</td></tr><tr><td>2,2-dimethylguanine, 2-methyladenine, 2-methylguanine,</td><td>0070 The invention is further directed to transfection</td></tr><tr><td>3-methylcytosine, 5-methylcytosine, N6-adenine, 7-meth</td><td>complexes, which include small RNA, such as siRNA and a</td></tr><tr><td>ylguanine, 5-methylaminomethyluracil, 5-methoxyaminom</td><td>rosette nanotube. Transfection complexes in accordance with</td></tr><tr><td>ethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxy</td><td>the present invention may include any of the rosette nano</td></tr><tr><td>carboxymethyluracil, 5-methoxyuracil, 2-methylthio-D46</td><td>tubes of the present invention in combination with small RNA</td></tr><tr><td>isopentenyladenine, uracil-5-oxyacetic acid (V).</td><td>known to those of skill in the art.</td></tr><tr><td>Wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-me</td><td>0071 According to certain aspects, cells within the scope</td></tr><tr><td>thyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil,</td><td>of the present invention that can be transfected include osteo</td></tr><tr><td>uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid</td><td>blasts, fibroblasts, endothelial cells, stem cells, keratinocytes,</td></tr><tr><td>(v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypro</td><td>cardiac myocytes, chondrocytes, synoviocytes, mesenchy</td></tr><tr><td>pyl) uracil, (acp3)w, 2,6-diaminopurine and the like. Nucleic</td><td>mal stem cells, neural stem cells, islet cells, hepatocytes,</td></tr><tr><td>acid molecules may also be modified at the base moiety, Sugar</td><td>Smooth muscle cells, urothelial cells, neurons, Schwann cells,</td></tr><tr><td>moiety or phosphate backbone.</td><td>microglial cells, cancerous and non cancerous cells, epithelial</td></tr><tr><td>0067. According to certain aspects, nucleic acids or</td><td>cells, endothelial cells, myofibroblasts, osteoclasts, macroph</td></tr><tr><td>polypeptides includes small RNA being a duplex of between</td><td>ages, leukocytes, osteocytes, astrocytes etc. and the like.</td></tr><tr><td>about 10 to about 30 nucleic acids, between about 15 to about</td><td>Additional cells include bacterial cells such as Staphylococ</td></tr><tr><td>25 nucleic acids and between about 20 to about 23 nucleic</td><td>cus aureus, Staphylococcus epidermis, Pseudomonas aerugi</td></tr><tr><td>acids, and any values and ranges in between whether over</td><td>nosa, MRSA, E. coli, candida (yeast), Candida albacans,</td></tr><tr><td>lapping or not. The small RNA can be formed by one or more</td><td>Streptococcus pneumoniae, Neisseria meningitides, Haemo</td></tr><tr><td>oligonucleotides. Small RNA includes RNA commonly</td><td>philus influenzae, Streptococcus agalactiae, Listeria mono</td></tr><tr><td>referred to as interference RNA, dsRNA, ssRNA, saRNA,</td><td>cytogenes, Mycoplasma pneumoniae, Chlamydia pneumo</td></tr><tr><td>siRNA or miRNA or their derivatives, analogs, mimics and</td><td>niae, Legionella pneumophila, Mycobacterium, tuberculosis,</td></tr><tr><td>inhibitors. According to certain aspects, siRNA is involved in</td><td>Streptococcus pyogenes, Chlamydia trachomatis, Neisseria</td></tr><tr><td>the RNA interference (RNAi) pathway, where it interferes</td><td>gonorrhoeae, Treponema pallidum, Ureaplasma urealyti</td></tr><tr><td>with the expression of a specific gene. In addition to their role</td><td>cum, Haemophilus ducreyi, Helicobacter pylori, Campylo</td></tr><tr><td>in the RNAi pathway, siRNAs also act in the RNAi-related</td><td>bacter jejuni, Salmonella, Shigella, Clostridium, Enterobac</td></tr><tr><td>pathways. siRNA within the scope of the present disclosure</td><td>teriaceae, Staphylococcus saprophyticus and the like. The</td></tr><tr><td>includes double stranded RNA of about 21 nucleotides with a</td><td>above list is intended to be exemplary and not exhaustive. One</td></tr><tr><td>2 nucleotide 3' overhang on either end of the siRNA. Each</td><td>of skill in the art will readily be able to identify additional</td></tr><tr><td>siRNA strand has a 5" phosphate group and a 3’ hydroxyl</td><td>cells within the scope of the present disclosure.</td></tr><tr><td>(—OH) group. The structure is the result of processing by</td><td>0072 According to aspects of the present disclosure, com</td></tr><tr><td>dicer, an enzyme that converts either long dsRNAs or small</td><td>posites of rosette nanotubes and small RNA can be combined</td></tr><tr><td>hairpin RNAs into siRNAs. Particular exemplary sequences</td><td>with a pharmaceutically acceptable agent and administered as</td></tr><tr><td>of siRNA are readily available to those of skill in the art</td><td>a delivery composition to an individual for therapeutic pur</td></tr><tr><td>through published literature and siRNA is commercially</td><td>poses. As used herein, a “pharmaceutically acceptable agent'</td></tr><tr><td>available from, for example, Qiagen. It is to be understood</td><td>(such as a salt, carrier, excipient or diluent) is a component</td></tr><tr><td>that the present disclosure is not to be limited to any particular</td><td>which (1) is compatible with the RNT/small RNA composites</td></tr><tr><td>siRNA sequence, but rather the present disclosure broadly</td><td>in that it can be included in the delivery composition-without</td></tr><tr><td>describes the incorporation of siRNA into or with rosette</td><td>eliminating the capacity of the RNT/small RNA composites</td></tr><tr><td>nanotubes. One of skill in the art will readily recognize that all</td><td>to transfect cells and deliver small RNA; and (2) where the</td></tr><tr><td>siRNA sequences, given the similar structure and function of</td><td>delivery composition is intended for therapeutic uses, is Suit</td></tr><tr><td>covalently connected nucleotides, can be incorporated into or</td><td>able for use with an animal (e.g., a human) without undue</td></tr></table></page>
<page number="33">
<table data-filename="Qian Chen - 2014 - NANOTUBES AS CARRIERS OF NUCLEIC ACIDS INTO CELLS , Patent App(2).pdf" data-page="33" data-table="1"><tr><td>US 2014/0171482 A1</td><td>Jun. 19, 2014</td></tr><tr><td>adverse side effects, such as toxicity, irritation, and allergic</td><td>Cells are then contacted with the complex. According to one</td></tr><tr><td>response. Side effects are “undue' when their risk outweighs</td><td>aspect, one of skill in the art will recognize from the benefit of</td></tr><tr><td>the benefit provided by the pharmaceutical agent.</td><td>the present disclosure that doses, concentrations, ratios and</td></tr><tr><td>0073. The term “small RNA is used as it is in the art, and</td><td>conditions of RNT/nucleic acids incorporation can be within</td></tr><tr><td>includes a duplex of RNA (30 bases or less in each strand) that</td><td>ranges. For example, between about 1 uL to about 100 uL, for</td></tr><tr><td>targets mRNA. Small RNA may be chemically or enzymati</td><td>example 10 uL, of 1 mg/mL RNTs can be mixed with about 4</td></tr><tr><td>cally synthesized. Small RNA in accordance with the present</td><td>uL to about 100LL, for example 20LL, of 5uM nucleic acids,</td></tr><tr><td>invention may be incorporated and then activated in RISC</td><td>such as siRNA, miRNA, nucleic acid probes or other nucleic</td></tr><tr><td>(RNA-induced silencing complex).</td><td>acids, at a temperature of between about 0°C. to about 37°C.</td></tr><tr><td>0074. A “therapeutically effective amount” is an amount</td><td>for between about 0.5 hours to about 48 hours and added into</td></tr><tr><td>necessary to prevent, delay or reduce the severity of the onset</td><td>1 mL cell culture medium for transfection. For example, the</td></tr><tr><td>of disease, or an amount necessary to arrest or reduce the</td><td>combination of RNT and nucleic acids can be maintained at</td></tr><tr><td>severity of an ongoing disease, and also includes an amount</td><td>4°C. for 24 hours or can be maintained at room temperature</td></tr><tr><td>necessary to enhance normal physiological functioning.</td><td>for two hours. Mixing can be accomplished by simple mixing,</td></tr><tr><td>0075. The word “transfect” is broadly used herein to refer</td><td>mixing while heating to about 60° C. to about 100° C., soni</td></tr><tr><td>to introduction of an exogenous compound, such as a poly</td><td>cation or other methods known to those of skill in the art. If</td></tr><tr><td>nucleotide sequence, into a prokaryotic or eukaryotic cell; the</td><td>heated, the combination may then be subjected to a tempera</td></tr><tr><td></td><td>ture of between about 0°C. to about 37° C. for between about</td></tr><tr><td>term includes, without limitation, introduction of an exogenous nucleic acid into a cell, which may result in a perma</td><td>0.5 hours to about 48 hours to result information or assembly</td></tr><tr><td>nent or temporary alteration of genotype in an immortal or</td><td>of the nanotube/nucleic acid complex.</td></tr><tr><td>non-immortal cell line. Accordingly, embodiments of the</td><td>007.9 The present invention also provides methods of</td></tr><tr><td>present disclosure include the introduction of a polynucle</td><td>treating diseases comprising using the complexes or compo</td></tr><tr><td>otide sequence to either be expressed or to inhibit expression</td><td>sitions of the present invention. In particular, methods are</td></tr><tr><td>of a target gene.</td><td>provided for treating a patient having a disease, by adminis</td></tr><tr><td>0076. In general, a cell to be transfected includes, but is not</td><td>tering to the patient a therapeutically effective amount of a</td></tr><tr><td>limited to, any animal, plant or bacterial cell that is suscep</td><td>complex or composition of the present invention. For in vivo</td></tr><tr><td>tible to intracellular delivery of DNA or RNA such as siRNA</td><td>therapies based on local injection (e.g., intratumoral, intra</td></tr><tr><td>using the transfection complex of the present invention either</td><td>muscularly, into the peritoneal cavity, intracardiac, and aero</td></tr><tr><td>in vitro or in vivo. For example, cells from different species</td><td>solized treatments) the RNT/small RNA complex is advanta</td></tr><tr><td>Such as human, mouse, rat, pig, chicken, etc. may be used</td><td>geously water soluble and so may be administered as an</td></tr><tr><td>according to the present disclosure. Likewise, cells from dif</td><td>aqueous injection.</td></tr><tr><td>ferent tissues or organs, such as liver, fibroblast, beast cells,</td><td>0080. In accordance with certain examples, complexes of</td></tr><tr><td>macrophages from the immune system, astrocytes from the</td><td>the present invention can be incorporated into pharmaceutical</td></tr><tr><td>neuronal system may be used. Likewise, primary cells</td><td>compositions suitable for administration. Such compositions</td></tr><tr><td>obtained directly from animals, plants or bacteria may be</td><td>typically comprise the complexes disclosed here and a phar</td></tr><tr><td>used and cell lines, such as commercially available immor</td><td>maceutically acceptable carrier. As used herein the term</td></tr><tr><td>talized cell, may be used. Likewise, normal cells may be used</td><td>“pharmaceutically acceptable carrier is intended to include</td></tr><tr><td>and diseased cells may be used. Such as cancer cells. For</td><td>any and all solvents; dispersion media, coatings, antibacterial</td></tr><tr><td>example, Suitable cellular targets include, without limitation,</td><td>and antifungal agents, isotonic and absorption delaying</td></tr><tr><td>epithelial cells, endothelial cells, keratinocytes, fibroblasts,</td><td>agents, and the like, compatible with pharmaceutical admin</td></tr><tr><td>muscle cells, hepatocytes, blood cells such as T lymphocytes,</td><td>istration. The use of Such media and agents for pharmaceuti</td></tr><tr><td>B lymphocytes, monocytes, macrophages, neutrophils, eosi</td><td>cally active substances is well known in the art. Exceptinsofar</td></tr><tr><td>nophils, megalaryocytes, granulocytes, various stem or pro</td><td>as any conventional media or agent is incompatible with the</td></tr><tr><td>genitor cells, in particular hematopoietic stem or progenitor</td><td>active compound, use thereof in the compositions is contem</td></tr><tr><td>cells, e.g., as obtained from bone marrow, umbilical cord</td><td>plated. Supplementary active compounds can also be incor</td></tr><tr><td>blood, peripheral blood, fetal liver, and the like. In certain</td><td>porated into the compositions.</td></tr><tr><td>aspects, the cell is selected from the group consisting of lung</td><td>I0081. In accordance with certain examples, a pharmaceu</td></tr><tr><td>cells, liver cells, endothelial cells, muscle cells, skin cells,</td><td>tical composition of the invention is formulated to be com</td></tr><tr><td>hematopoietic stem cells and tumor cells.</td><td>patible with its intended route of administration. Such phar</td></tr><tr><td>0077 According to certain embodiments, the cells include</td><td>maceutical compositions may be administered by inhalation,</td></tr><tr><td>one or more cells selected from the group consisting of trans</td><td>transdermally, orally, rectally, transmucosally, intestinally,</td></tr><tr><td>formed, recombinant, malignant, and primary cell lines. It is</td><td>parenterally, intramuscularly, Subcutaneously, intravenously</td></tr><tr><td>believed that the rosette nanotubes of the present invention</td><td>or other suitable methods that will be readily selected by the</td></tr><tr><td>will be effective as carriers of DNA or RNA Such as siRNA in</td><td>person of ordinary skill in the art, given the benefit of this</td></tr><tr><td>most, if not all cell types and cell lines. Since complexes of the</td><td>disclosure. For example, Solutions or Suspensions used for</td></tr><tr><td>rosette nanotubes and nucleic acids are composed of</td><td>parenteral, intradermal, or Subcutaneous application can</td></tr><tr><td>covalently bound base pairs, one of skill would expect that</td><td>include the following components: a sterile diluent Such as</td></tr><tr><td>such complexes will be universally recognized by all cell</td><td>water for injection, Saline Solution, fixed oils, polyethylene</td></tr><tr><td>types for transfecting purposes.</td><td>glycols, glycerin, propylene glycol or other synthetic Sol</td></tr><tr><td>0078 Methods of transfecting cells in accordance with the</td><td>vents; antibacterial agents such as benzyl alcohol or methyl</td></tr><tr><td>present invention may also include forming the transfection</td><td>parabens; antioxidants such as ascorbic acid or sodium</td></tr><tr><td>complex by combining in aqueous media the modules of the</td><td>bisulfite; chelating agents such as ethylenediaminetetraacetic</td></tr><tr><td>rosette nanotube and one or more DNA sequences and/or one</td><td>acid; buffers such as acetates, citrates or phosphates and</td></tr><tr><td>or more RNA sequences. The complex is allowed to form.</td><td>agents for the adjustment of tonicity Such as Sodium chloride</td></tr></table></page>
<page number="34">
<table data-filename="Qian Chen - 2014 - NANOTUBES AS CARRIERS OF NUCLEIC ACIDS INTO CELLS , Patent App(2).pdf" data-page="34" data-table="1"><tr><td>US 2014/0171482 A1</td><td></td><td></td><td></td><td colspan="2">Jun. 19, 2014</td></tr><tr><td colspan="3">or dextrose. pH can be adjusted with acids or bases, such as</td><td colspan="3">(i.e., a typically malignant tumor which resembles an imma</td></tr><tr><td colspan="3">hydrochloric acid or sodium hydroxide. The parenteral prepa</td><td colspan="2">ture or embryonic tissue) and the like.</td><td></td></tr><tr><td colspan="3">ration can be enclosed in ampules, disposable syringes or</td><td></td><td></td><td></td></tr><tr><td>multiple dose vials made of glass or plastic.</td><td></td><td></td><td>I0086</td><td>Examples of specific neoplasms</td><td>intended to be</td></tr><tr><td></td><td></td><td></td><td colspan="3">encompassed by the present invention include, but are not</td></tr><tr><td colspan="3">0082 Also encompassed are methods for treating a patient</td><td colspan="3">limited to, acute lymphoblastic leukemia; myeloid leukemia,</td></tr><tr><td colspan="3">having a disease, by administering to the patient cells that</td><td colspan="3">acute myeloid leukemia, childhood; adrenocortical carci</td></tr><tr><td colspan="3">have been transfected by the methods disclosed herein. An</td><td colspan="3">noma; AIDS-related cancers: AIDS-related lymphoma; anal</td></tr><tr><td colspan="3">aspect of an ex vivo delivery method of the present invention</td><td colspan="3">cancer, appendix cancer; astrocytoma (e.g., cerebellar, cere</td></tr><tr><td colspan="3">may include for example, (i) removing a cell from a subject;</td><td colspan="3">bral); atypical teratoid/rhabdoid tumor; basal cell carcinoma;</td></tr><tr><td colspan="3">(ii) introducing siRNA into a cell by contacting the cell with</td><td colspan="3">bile duct cancer, extrahepatic; bladder cancer, bone cancer,</td></tr><tr><td colspan="3">a delivery composition (transfection complex or composition</td><td colspan="3">osteosarcoma and malignant fibrous histiocytoma; brain</td></tr><tr><td colspan="3">comprising Such a transfection complex) comprising siRNA</td><td colspan="3">tumor (e.g., brain stem glioma, central nervous system atypi</td></tr><tr><td colspan="3">and a rosette nanotube; and (iii) reintroducing the cell into the</td><td colspan="3">cal teratoid/rhabdoid tumors, central nervous system</td></tr><tr><td colspan="3">Subject. In addition, nanotubes having nucleic acids com</td><td colspan="3">embryonal tumors, cerebellar astrocytoma, cerebral astrocy</td></tr><tr><td colspan="3">plexed therewith as described herein may be delivered in vivo</td><td colspan="3">toma/malignant glioma, craniopharyngioma, ependymoblas</td></tr><tr><td colspan="3">to an individual in need of treatment where the nanotubes</td><td colspan="3">toma, ependymoma, medulloblastoma, medulloepithelioma,</td></tr><tr><td colspan="3">having nucleic acids complexed therewith enter cells within</td><td colspan="3">pineal parenchymal tumors of intermediate differentiation,</td></tr><tr><td colspan="3">the individual and the nucleic acids regulate cellular expres</td><td colspan="3">Supratentorial primitive neuroectodermal tumors and/or pine</td></tr><tr><td colspan="3">sion of proteins. For example the nucleic acids may silence</td><td colspan="3">oblastoma, visual pathway and/or hypothalamic glioma,</td></tr><tr><td colspan="3">genes in a therapeutic manner to the extent that a protein is not</td><td>brain</td><td colspan="2">and spinal cord tumors); breast cancer; bronchial</td></tr><tr><td colspan="3">expressed resulting in treatment or the nucleic acids may be</td><td colspan="3">tumors; Burkitt lymphoma; carcinoid tumor (e.g., gas</td></tr><tr><td colspan="3">expressed by the cell to produce proteins in a therapeutic</td><td colspan="3">trointestinal); carcinoma of unknown primary; central ner</td></tr><tr><td>manner resulting in treatment.</td><td></td><td></td><td colspan="3">Vous system (e.g., atypical teratoid/rhabdoid tumor, embryo</td></tr><tr><td colspan="3">0083. Examples of genetic and/or non-neoplastic diseases</td><td colspan="3">nal tumors (e.g., lymphoma, primary); cerebellar</td></tr><tr><td colspan="3">potentially treatable with the complex, compositions, and</td><td colspan="3">astrocytoma; cerebral astrocytoma/malignant glioma; cervi</td></tr><tr><td colspan="3">methods include, but are not limited to the following: adenos</td><td colspan="3">cal cancer, chordoma; chronic lymphocytic leukemia;</td></tr><tr><td colspan="3">ine deaminase deficiency; purine nucleoside phosphorylase</td><td colspan="3">chronic myelogenous leukemia; chronic myeloproliferative</td></tr><tr><td colspan="3">deficiency; chronic granulomatous disease with defective</td><td colspan="3">disorders; colon cancer, colorectal cancer, craniopharyn</td></tr><tr><td colspan="3">p47phox; sickle cell with HbS, L-thalassemia; Faconi's ane</td><td colspan="3">gioma; cutaneous T-cell lymphoma; embryonal tumors, cen</td></tr><tr><td colspan="3">mia; familial hypercholesterolemia; phenylketonuria; orni</td><td colspan="3">tral nervous system; endometrial cancer; ependymoblastoma;</td></tr><tr><td colspan="3">thine transcarbamylase deficiency; apolipoprotein E defi</td><td colspan="3">ependymoma; esophageal cancer, Ewing family of tumors;</td></tr><tr><td colspan="3">ciency; hemophilia A and B; muscular dystrophy; cystic</td><td colspan="3">extracranial germ cell tumor; extragonadal germ cell tumor;</td></tr><tr><td colspan="3">fibrosis; Parkinsons, retinitis pigmentosa, lysosomal storage</td><td colspan="3">extrahepatic bile duct cancer, eye cancer (e.g., intraocular</td></tr><tr><td colspan="3">disease (e.g., mucopolysaccharide type 1, Hunter, Hurler and</td><td colspan="3">melanoma, retinoblastoma); gallbladder cancer, gastric can</td></tr><tr><td colspan="3">Gaucher), diabetic retinopathy, human immunodeficiency</td><td colspan="3">cer; gastrointestinal tumor (e.g., carcinoid tumor, stromal</td></tr><tr><td colspan="3">virus disease virus infection, acquired anemia, cardiac and</td><td colspan="3">tumor (gist), stromal cell tumor); germ cell tumor (e.g.,</td></tr><tr><td colspan="3">peripheral vascular disease, osteoporosis and arthritis. In</td><td colspan="3">extracranial, extragonadal, ovarian); gestational trophoblas</td></tr><tr><td colspan="3">Some of these examples of diseases, the therapeutic gene may</td><td colspan="3">tic tumor; glioma (e.g., brain stem, cerebral astrocytoma);</td></tr><tr><td colspan="3">encode a replacement enzyme or protein of the genetic or</td><td colspan="3">hairy cell leukemia; head and neck cancer; hepatocellular</td></tr><tr><td colspan="3">acquired disease, an antisense or ribozyme molecule, a decoy</td><td colspan="3">cancer, Hodgkin lymphoma; hypopharyngeal cancer; hypo</td></tr><tr><td>molecule, or a Suicide gene product.</td><td></td><td></td><td colspan="3">thalamic and visual pathway glioma; intraocular melanoma;</td></tr><tr><td></td><td></td><td></td><td colspan="3">islet cell tumors; Kaposi sarcoma, kidney cancer, large cell</td></tr><tr><td colspan="3">0084 Ex vivo and in vivo gene therapy with siRNA could</td><td colspan="3">tumors; laryngeal cancer (e.g., acute lymphoblastic, acute</td></tr><tr><td colspan="3">also be used in cancer. These RNAi applications toward can</td><td colspan="3">myeloid); leukemia (e.g., acute myeloid, chronic lympho</td></tr><tr><td colspan="3">cer include, but are not limited to, 1) reducing expression of</td><td colspan="3">cytic, chronic myelogenous, hairy cell); lip and/or oral cavity</td></tr><tr><td colspan="3">growth factors, reducing proteins that augment the cell cycle</td><td colspan="3">cancer, liver cancer; lung cancer (e.g., non-Small cell, Small</td></tr><tr><td colspan="3">(e.g., Raf-1, P1-3 kinase), growth factor receptors (e.g.,</td><td>cell);</td><td colspan="2">lymphoma (e.g., AIDS-related, Burkitt, cutaneous</td></tr><tr><td colspan="3">EGFR, Her-2), or proteins critical for supporting cells of the</td><td colspan="3">Tcell, Hodgkin, non-Hodgkin, primary central nervous sys</td></tr><tr><td colspan="3">tumor (e.g., VEGF, VEGFR1-2 for tumor endothelial cells);</td><td colspan="3">tem); macroglobulinemia, Waldenström; malignant fibrous</td></tr><tr><td colspan="3">2) targeting or reducing expression of factors that are anti</td><td colspan="3">histiocytoma of bone and/or osteosarcoma; medulloblas</td></tr><tr><td colspan="3">apoptotic (e.g., BCL-2); and 3) targeting proteins or enzymes</td><td>toma;</td><td colspan="2">medulloepithelioma: melanoma; merkel cell carci</td></tr><tr><td>that reduce immune activation toward tumor.</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>noma;</td><td colspan="2">mesothelioma; metastatic squamous neck cancer,</td></tr><tr><td>0085 Cancers or neoplasms contemplated</td><td>within</td><td>the</td><td colspan="3">mouth cancer, multiple endocrine neoplasia syndrome; mul</td></tr><tr><td colspan="3">Scope of the disclosure include, but are not limited to, carci</td><td colspan="3">tiple myeloma/plasma cell neoplasm; mycosis fungoides;</td></tr><tr><td colspan="3">nomas (i.e., malignant tumors derived from epithelial cells</td><td colspan="3">myelodysplastic syndromes; myelodysplastic/myeloprolif</td></tr><tr><td colspan="3">Such as, for example, common forms of breast, prostate, lung</td><td colspan="3">erative diseases; myelogenous leukemia (e.g., chronic, acute,</td></tr><tr><td colspan="3">and colon cancer), sarcomas (i.e., malignant tumors derived</td><td colspan="3">multiple); myeloproliferative disorders, chronic; nasal cavity</td></tr><tr><td colspan="3">from connective tissue or mesenchymal cells), lymphomas</td><td colspan="3">and/or paranasal sinus cancer, nasopharyngeal cancer; neu</td></tr><tr><td colspan="3">(i.e., malignancies derived from hematopoietic cells), leuke</td><td colspan="3">roblastoma; non-Hodgkin lymphoma; non-Small cell lung</td></tr><tr><td colspan="3">mias (i.e., malignancies derived from hematopoietic cells),</td><td colspan="3">cancer, oral cancer, oral cavity cancer, oropharyngeal cancer,</td></tr><tr><td colspan="3">germ cell tumors (i.e., tumors derived from totipotent cells. In</td><td colspan="3">osteosarcoma and/or malignant fibrous histiocytoma of bone;</td></tr><tr><td colspan="3">adults most often found in the testicle or ovary; in fetuses,</td><td colspan="3">ovarian cancer (e.g., ovarian epithelial cancer, ovarian germ</td></tr><tr><td colspan="3">babies and young children, most often found on the body</td><td colspan="3">cell tumor, ovarian low malignant potential tumor); pancre</td></tr><tr><td colspan="3">midline, particularly at the tip of the tailbone), blastic tumors</td><td colspan="3">atic cancer (e.g., islet cell tumors); papillomatosis; paranasal</td></tr></table></page>
<page number="35">
<table data-filename="Qian Chen - 2014 - NANOTUBES AS CARRIERS OF NUCLEIC ACIDS INTO CELLS , Patent App(2).pdf" data-page="35" data-table="1"><tr><td colspan="3">US 2014/0171482 A1</td><td>Jun. 19, 2014</td></tr><tr><td colspan="3">sinus and/or nasal cavity cancer; parathyroid cancer, penile</td><td>nanotubes formed from the compounds of Formula I (RNTs)</td></tr><tr><td>cancer,</td><td>pharyngeal</td><td>cancer, pheochromocytoma; pineal</td><td>or with rosette nanotubes formed from the compounds of</td></tr><tr><td colspan="3">parenchymal tumors of intermediate differentiation; pine</td><td>Formula II (TBLs). RNTs were formed using a compound of</td></tr><tr><td colspan="3">oblastoma and Supratentorial primitive neuroectodermal</td><td>Formula I where R is methyl, X is nitrogen, R is the linker</td></tr><tr><td>tumors;</td><td colspan="2">pituitary tumor, plasma cell neoplasm/multiple</td><td>(CH2) and Y is lysine. TBLS were formed using a compound</td></tr><tr><td colspan="3">myeloma; pleuropulmonary blastoma; primary central ner</td><td>of Formula II where R is methyl, X is nitrogen, R is the</td></tr><tr><td colspan="3">Vous system lymphoma; prostate cancer, rectal cancer, renal</td><td>linker (CH) and Y is NH. Specifically and without limi</td></tr><tr><td colspan="3">cell cancer, renal, pelvis and/or ureter, transitional cell can</td><td>tation, 1 mg of modules of rosette nanotubes in powder form</td></tr><tr><td colspan="3">cer, respiratory tract carcinoma involving the nut gene on</td><td>were dissolved in 1 ml of distilled water and sonicated and</td></tr><tr><td colspan="3">chromosome 15; retinoblastoma, rhabdomyosarcoma; Sali</td><td>heated to boiling so that rosette nanotubes were formed. The</td></tr><tr><td colspan="3">vary gland cancer, sarcoma (e.g., Ewing family of tumors,</td><td>structures of the rosette nanotubes were described in U.S. Pat.</td></tr><tr><td colspan="3">Kaposi, soft tissue, uterine); Sézary syndrome; skin cancer</td><td>No. 6,696,565; Fenniri, J. Am. Chem. Soc, 2001, 123,3854</td></tr><tr><td colspan="3">(e.g., non-melanoma, melanoma, merkel cell); Small cell lung</td><td>3855; and Moralez, J. Am. Chem. Soc. 2005, 127, 8307-8309</td></tr><tr><td colspan="3">cancer, Small intestine cancer, Soft tissue sarcoma; squamous</td><td>each of which are hereby incorporated by reference in their</td></tr><tr><td colspan="3">cell carcinoma; squamous neck cancer with occult primary,</td><td>entireties. One particular module forming the rosette nano</td></tr><tr><td colspan="3">metastatic; Stomach cancer, Supratentorial primitive neuroec</td><td>tube is shown in FIG. 1. The solution was cooled to room</td></tr><tr><td colspan="3">todermal tumors; T-cell lymphoma, cutaneous; testicular can</td><td>temperature. 2 ul of the solution was mixed with 45 ul of an</td></tr><tr><td colspan="3">cer; throat cancer; thymoma and/or thymic carcinoma; thy</td><td>siRNA solution containing 0.16 nmol FITC labeled siRNA</td></tr><tr><td colspan="3">roid cancer, transitional cell cancer of the renal, pelvis and/or</td><td>(Qiagen, Hilden, Germany) at 4C overnight.</td></tr><tr><td colspan="3">ureter, trophoblastic tumor; unknown primary site carci</td><td>0091 Alternatively, modules of rosette nanotubes as</td></tr><tr><td colspan="3">noma; urethral cancer, uterine cancer, endometrial; uterine</td><td>described above in powder form are combined with a water</td></tr><tr><td colspan="3">sarcoma; vaginal cancer, visual pathway and/or hypotha</td><td>and a solution of an siRNA solution containing FITC labeled</td></tr><tr><td colspan="3">lamic glioma; Vulvar cancer, Waldenström macroglobuline</td><td>siRNA (Qiagen, Hilden, Germany) are sonicated and heated</td></tr><tr><td colspan="3">mia; Wilms tumor and the like. For a review, see the National</td><td>to boiling. The combination is then cooled to room tempera</td></tr><tr><td colspan="3">Cancer Institute's Worldwide Website (cancer.gov/cancer</td><td>ture and maintained at 4°C. overnight.</td></tr><tr><td colspan="3">topics/alphalist). One of skill in the art will understand that</td><td>0092 Alternatively, purified rosette nanotubes were ster</td></tr><tr><td colspan="3">this list is exemplary only and is not exhaustive, as one of skill</td><td>ilized in boiled water. 0.5 ng/ml rosette nanotubes were incu</td></tr><tr><td colspan="3">in the art will readily be able to identify additional cancers</td><td>bated with 100 nmol FITC labeled Scrambled siRNA or</td></tr><tr><td colspan="3">and/or neoplasms based on the disclosure herein.</td><td>HDAC4 siRNAs (Qiagen, Hilden, Germany) at CC for over</td></tr><tr><td style="text-align: right">0087</td><td colspan="2">Recombinant cells may be produced using the com</td><td>night.</td></tr><tr><td colspan="3">plexes of the present invention. Resulting recombinant cells</td><td>0093 Small RNAs were incorporated into and complexed</td></tr><tr><td colspan="3">can be delivered to a subject by various methods known in the</td><td>with rosettes nanotubes. 1 uL of 50M scrambled siRNA was</td></tr><tr><td>art. In</td><td colspan="2">certain embodiments, the recombinant cells are</td><td>incorporated with 5 uL of 1 mg/mL RNTs according to the</td></tr><tr><td colspan="3">injected, e.g., Subcutaneously. In other embodiments, recom</td><td>method described above. Then, the solution was added into 1</td></tr><tr><td colspan="3">binant skin cells may be applied as a skin graft onto a patient.</td><td>mL water for UV-Vis measurement. Solutions of siRNA only</td></tr><tr><td colspan="3">Recombinant blood cells (e.g., hematopoietic stem or pro</td><td>and RNT only were also prepared at the same concentration</td></tr><tr><td colspan="3">genitor cells) are preferably administered intravenously. The</td><td>as above for UV-Vis measurement. As shown in FIG. 2, the</td></tr><tr><td colspan="3">cells can also be encapsulated in a Suitable vehicle and then</td><td>incorporation was determined by a lower light absorbance of</td></tr><tr><td colspan="3">implanted in the subject (see, e.g., Dionne et al. PCT Publi</td><td>the RNT/siRNA composites in UV-Vis spectroscopy com</td></tr><tr><td colspan="3">cation WO92/19195, dated Nov. 12, 1992). The amount of</td><td>pared with the total absorbance of siRNA and RNTs tested</td></tr><tr><td colspan="3">cells administered depends on a variety of factors known in</td><td>separately. This demonstrated that the small RNA and the</td></tr><tr><td colspan="3">the art, for example, the desired effect, subject state, rate of</td><td>RNTs were physically mixed together and with their bases</td></tr><tr><td colspan="3">expression of the chimeric polypeptides, etc., and can readily</td><td>also packed together.</td></tr><tr><td colspan="3">be determined by one skilled in the art.</td><td>0094 Moreover, a CD spectroscopy was applied to detect</td></tr><tr><td></td><td></td><td></td><td>the change in the chirality of RNT/siRNA composites and to</td></tr><tr><td></td><td></td><td>EXAMPLES</td><td>verify their physical incorporation. 1 uL of 50 uM scrambled</td></tr><tr><td style="text-align: right">0088.</td><td colspan="2">The following examples are specific embodiments</td><td>siRNA was incorporated with 5uL of 1 mg/mL RNTs accord</td></tr><tr><td colspan="3">of the present invention but are not intended to limit it.</td><td>ing to the method described above. Then, the solution was</td></tr><tr><td></td><td></td><td></td><td>added into 1 mL water for CD spectroscopy. Solutions of</td></tr><tr><td></td><td></td><td>Example 1</td><td>siRNA only and RNT only were also prepared at the same</td></tr><tr><td></td><td></td><td></td><td>concentration as above for the experiment. As shown in FIG.</td></tr><tr><td></td><td colspan="2">Cell Culture of Chondrocytes</td><td>3, a change of molecular chirality demonstrated the incorpo</td></tr><tr><td></td><td></td><td></td><td>ration between RNTS and siRNA.</td></tr><tr><td style="text-align: right">0089.</td><td colspan="2">Primary mouse chondrocytes were isolated from the</td><td></td></tr><tr><td colspan="3">rib cage of 5 days old mice. Human chondrocyte cell line</td><td>0.095 Thermo analysis experiments were conducted to</td></tr><tr><td colspan="3">C2812 and ADTC5 mouse chondrocyte were incubated in</td><td>determine disassembly of the siRNAs from RNTs. 1 uL of 50</td></tr><tr><td colspan="3">growth media including DMEM/F12 supplement with 10%</td><td>uM scrambled siRNA was incorporated with 5 uL of 1</td></tr><tr><td colspan="2">fetal calf serum.</td><td></td><td>mg/mL RNTs as the method mentioned above. Then, the</td></tr><tr><td></td><td></td><td></td><td>solution was added into 0.3 mL water for thermo analysis.</td></tr><tr><td></td><td></td><td>Example 2</td><td>Temperatures increased from 4°C. to 99°C. with 1 minute</td></tr><tr><td></td><td></td><td></td><td>equilibrium time at every temperature. RNT only solution</td></tr><tr><td></td><td colspan="2">Preparation of RNT/Nucleic Acid Complexes</td><td>was also prepared at the same concentration as above. As</td></tr><tr><td></td><td></td><td></td><td>shown in FIG. 4, transition temperatures of RNTs in RNT/</td></tr><tr><td style="text-align: right">0090</td><td colspan="2">According to an aspect of the present disclosure,</td><td>siRNA composites in thermo analysis experiments were</td></tr><tr><td colspan="3">nucleic acids are incorporated or complexed with rosette</td><td>lower than the melting temperatures of RNTs alone. This</td></tr></table></page>
<page number="36">
<table data-filename="Qian Chen - 2014 - NANOTUBES AS CARRIERS OF NUCLEIC ACIDS INTO CELLS , Patent App(2).pdf" data-page="36" data-table="1"><tr><td colspan="2">US 2014/0171482 A1</td><td></td><td>Jun. 19, 2014</td></tr><tr><td colspan="2">demonstrated the ability of siRNAs to disassemble from</td><td colspan="2">with RNT/siRNA complex for 24 hours and observed by</td></tr><tr><td colspan="2">RNTs so that after delivery into a cell, siRNA could release</td><td colspan="2">confocal microscophy. Briefly, the cells were washed twice</td></tr><tr><td colspan="2">from RNTs for desired functions.</td><td colspan="2">with PBS and then fixed in 4% formalin. Thereafter, cells</td></tr><tr><td style="text-align: right">0096</td><td>Electrophoresis was carried out to determine the</td><td colspan="2">were permeabilized with PBS/0.1% TritonX-100 and stained</td></tr><tr><td colspan="2">incorporation of siRNAs into RNTs. 1 u, of 50 uMscrambled</td><td colspan="2">with rhodamine and incubated with DAPI for nuclear coun</td></tr><tr><td colspan="2">siRNA was incorporated with or without 5 uL of 1 mg/mL</td><td colspan="2">terstaining. The internalized HDAC4 siRNA accumulated in</td></tr><tr><td colspan="2">RNTs according to the method described above. 4% agarose</td><td colspan="2">the cytoplasm and colocalized with HDAC4 protein as shown</td></tr><tr><td colspan="2">gel was prepared for electrophoresis with ethidium bromide</td><td colspan="2">in FIG. 9. In particular, FIGS. 9(E) and 9(F) are 2D and 3D</td></tr><tr><td colspan="2">as fluorescence stain. Then, RNT/siRNA and RNT solution</td><td colspan="2">images of green fluorescent siRNA delivered by RNTs inside</td></tr><tr><td colspan="2">were mixed glycerol and the gel was run under 30V at 4°C.</td><td colspan="2">a chondrocyte. Red fluorescence indicates the cytoskeleton</td></tr><tr><td colspan="2">for 2 hours. Electrophoresis demonstrated the incorporation</td><td colspan="2">and blue fluorescence indicates the cell nuclei.</td></tr><tr><td colspan="2">between RNTs and siRNAs and RNT/siRNA composites</td><td></td><td></td></tr><tr><td colspan="2">have a neutral total charge compared to negatively charged</td><td></td><td>Example 5</td></tr><tr><td colspan="2">siRNA as shown in FIG. 5.</td><td></td><td></td></tr><tr><td style="text-align: right">0097</td><td>Atomic force microscopic studies were carried out</td><td colspan="2">Inhibition of Protein Expression Using RNT/siRNA</td></tr><tr><td colspan="2">to analyze the surface of a network of RNTs and RNT/siRNA</td><td></td><td>Complexes</td></tr><tr><td colspan="2">composites. RNT/siRNA composites were prepared as</td><td style="text-align: right">0100.</td><td>To evaluate the ability of RNT/siRNA complex to</td></tr><tr><td colspan="2">described above. 6 ul acetone was added to 10ul of a solution</td><td colspan="2">interfere with RNA in primary mouse chondrocytes, RNA</td></tr><tr><td colspan="2">of RNT/siRNA solution and a drop placed onto a clean glass</td><td colspan="2">was isolated and HDAC4 gene silencing was evaluated by</td></tr><tr><td colspan="2">slide. After air-drying, the glass slide was analyzed under</td><td colspan="2">real-time PCR. Chondrocytes were lyzed in RIPA lysis buffer</td></tr><tr><td colspan="2">atomic force microscopy. As shown in FIG. 6, RNTs formed</td><td colspan="2">and equal amount of cell lysates were separated by 10%</td></tr><tr><td colspan="2">a network morphology in a relatively high concentration. As</td><td colspan="2">SDS-PAGE and transferred on a nitrocellulose membrane.</td></tr><tr><td colspan="2">shown in FIG. 7A, RNTs complexed with small RNAs</td><td colspan="2">Membranes were blot with HDAC4 or Actin antibody. Immu</td></tr><tr><td colspan="2">showed regions of regions RNAs referred to as “clots’ indi</td><td colspan="2">noblotting coupled with fluorescent signal detection with an</td></tr><tr><td colspan="2">cated by circles and “bundles' indicated by the arrow. Trans</td><td colspan="2">Odyssey fluorescence scanner. As shown in FIG. 10A,</td></tr><tr><td colspan="2">mission electron microscopy was also used to analyze the</td><td colspan="2">expression level of HDAC4 mRNA was suppressed by nearly</td></tr><tr><td colspan="2">morphologies of RNTs and RNT/siRNA composites. RNT/</td><td colspan="2">80%. As shown in FIG. 10B, Western blot analysis indicated</td></tr><tr><td colspan="2">siRNA composites were prepared as described above. A cop</td><td colspan="2">that HDAC4 protein expression was successfully inhibited.</td></tr><tr><td colspan="2">per grid was dip into RNT or RNT/siRNA solutions. After</td><td colspan="2">The efficient gene silencing indicates that siRNA delivered by</td></tr><tr><td colspan="2">air-drying, the copper grid was negatively stained with uranyl</td><td colspan="2">RNT was functional in the cells. FIG. 10C depicts the quan</td></tr><tr><td colspan="2">acetate and analyzed under transmission electron micros</td><td colspan="2">titative analysis of the Western blots of FIG. 10B demonstrat</td></tr><tr><td colspan="2">copy. As shown in FIG. 7(B), RNTs formed a network mor</td><td colspan="2">ing that siRNAs were highly functional after delivery by</td></tr><tr><td colspan="2">phology. Consistent with atomic force microscopy: FIG.7(C)</td><td>RNTs into cells.</td><td></td></tr><tr><td colspan="2">shows that RNTs complexed with small RNAs and experi</td><td></td><td></td></tr><tr><td colspan="2">enced a morphological transformation from net-work struc</td><td></td><td>Example 6</td></tr><tr><td colspan="2">tures to particle-like structures.</td><td></td><td></td></tr><tr><td></td><td>Example 3</td><td></td><td>Alteration of miRNA Expression Using</td></tr><tr><td></td><td></td><td></td><td>RNT/miR365 Mimic or Inhibitor Complexes</td></tr><tr><td></td><td>Chondrocytes Transfected with RNT/siRNA</td><td></td><td></td></tr><tr><td></td><td>Complexes</td><td style="text-align: right">0101</td><td>To evaluate the ability of RNTs to deliver miRNA</td></tr><tr><td></td><td></td><td colspan="2">mimic into cells, RNT/miR365 mimic complexes were pre</td></tr><tr><td style="text-align: right">0098.</td><td>To visualize internalization of siRNA by RNT deliv</td><td colspan="2">pared using the methods described above. Human chondro</td></tr><tr><td colspan="2">ery into chondrocytes, RNTS/FITC-siRNA complex were</td><td colspan="2">cytes (C2812) were contacted with the complexes and then</td></tr><tr><td colspan="2">added into ADTC5 mouse chondrocyte cell lines and incu</td><td colspan="2">the expression levels of miR365 were determined. Briefly,</td></tr><tr><td colspan="2">bated for 24 hours. The transfected cells were washed twice</td><td colspan="2">total RNA was extracted from cells using a commercially</td></tr><tr><td colspan="2">with PBS and then fixed in 4% formalin. Thereafter, cells</td><td colspan="2">available kit by following the manufacturer's instructions.</td></tr><tr><td colspan="2">were permeabilized with PBS/0.1% TritonX-100 and stained</td><td colspan="2">Then, the RNA was reverse transcribed using the miscript</td></tr><tr><td colspan="2">with HDAC4 antibody and incubated with DAPI for nuclear</td><td colspan="2">reverse transcription kit and analyzed by real-time PCR using</td></tr><tr><td colspan="2">counterstaining. Confocal imaging was performed with a</td><td colspan="2">the appropriate miscript primer assay as per the manufactur</td></tr><tr><td colspan="2">Zeiss AXiovert confocal laser scanning microscope. Fluores</td><td colspan="2">er's instructions. For gene expression assay, the same amount</td></tr><tr><td colspan="2">cence microscopy of the treated cells revealed internalized</td><td colspan="2">of RNA was used for each sample. The 18 S RNA was</td></tr><tr><td colspan="2">RNT/SiRNA. FIG. 8 depicts light (A and C) and fluorescent</td><td colspan="2">amplified at the same time and used as an internal control. As</td></tr><tr><td colspan="2">(Band D) pictures of chondrocytes cultured with only FITC</td><td colspan="2">shown in FIG. 11, the RNT/miR365 mimic complexes suc</td></tr><tr><td colspan="2">RNA (A and B) or with FITC-RNA-RNTs (C and D). As</td><td colspan="2">cessfully delivered miR365 mimic into cells and the delivered</td></tr><tr><td colspan="2">shown in FIG.8B, fluorescence labeled siRNA alone was not</td><td colspan="2">miR365 mimic was functional to increase miR365 gene</td></tr><tr><td colspan="2">able to enter the cells. After incubation of fluorescent labeled</td><td>expression.</td><td></td></tr><tr><td colspan="2">siRNA with RNT as a carrier, the cells showed intracellular</td><td style="text-align: right">0102)</td><td>To evaluate the ability of RNTs to deliver miRNA</td></tr><tr><td colspan="2">green fluorescent signals as shown in FIG. 8D. This demon</td><td colspan="2">inhibitor into cells, RNT/miR365 inhibitor complexes were</td></tr><tr><td colspan="2">strates efficient uptake of RNT/RNA by chondrocytes.</td><td colspan="2">prepared using the methods described above. Human chon</td></tr><tr><td></td><td>Example 4</td><td colspan="2">drocytes (C2812) were contacted with the complexes and</td></tr><tr><td></td><td></td><td colspan="2">then the expression levels of miR365 were determined.</td></tr><tr><td colspan="2">Primary Chondrocytes Transfected with RNT/siRNA</td><td colspan="2">Briefly, total RNA was extracted from cells using a commer</td></tr><tr><td></td><td>Complexes</td><td colspan="2">cially available kit by following the manufacturers instruc</td></tr><tr><td>0099]</td><td>To test whether RNT can carry siRNA into primary</td><td colspan="2">tions. Then, the RNA was reverse transcribed using the mis</td></tr><tr><td colspan="2">chondrocytes, mouse primary chondrocytes were incubated</td><td colspan="2">cript reverse transcription kit and analyzed by real-time PCR</td></tr></table></page>
<page number="37">
<table data-filename="Qian Chen - 2014 - NANOTUBES AS CARRIERS OF NUCLEIC ACIDS INTO CELLS , Patent App(2).pdf" data-page="37" data-table="1"><tr><td colspan="2">US 2014/0171482 A1</td><td></td><td>Jun. 19, 2014</td></tr><tr><td colspan="2">using the appropriate miscript primer assay as per the manu</td><td colspan="2">GAPDH molecular beacon targeting GAPDH expression</td></tr><tr><td colspan="2">facturers instructions. For gene expression assay, the same</td><td colspan="2">complex for 24 hours and observed by confocal microscopy.</td></tr><tr><td colspan="2">amount of RNA was used for each sample. The 18 S RNA was</td><td colspan="2">Briefly, the cells were washed twice with PBS and then fixed</td></tr><tr><td colspan="2">amplified at the same time and used as an internal control. As</td><td colspan="2">in 4% formalin for confocal microscopy. FIG. 14 depicts light</td></tr><tr><td colspan="2">shown in FIG. 12A, the RNT/miR365 inhibitor complexes</td><td colspan="2">(A and C) and fluorescent (B and D) pictures of chondrocytes</td></tr><tr><td colspan="2">successfully delivered miR365 inhibitor into the cells and the</td><td colspan="2">cultured with only GAPDH molecular beacon (A and B) or</td></tr><tr><td colspan="2">delivered miR365 inhibitor was functional to decrease</td><td colspan="2">with RNT/GAPDH molecular beacon complex (Cand D). As</td></tr><tr><td colspan="2">miR365 gene expression.</td><td colspan="2">shown in FIG. 14B, fluorescence labeled GAPDH molecular</td></tr><tr><td style="text-align: right">(0103)</td><td>To evaluate the ability of RNTs such as TBLs to</td><td colspan="2">beacon alone was notable to enter the cells. After incubation</td></tr><tr><td colspan="2">deliver miRNA inhibitor into cells, TBL/miR365 inhibitor</td><td colspan="2">of fluorescent labeled GAPDH molecular beacon with RNT</td></tr><tr><td colspan="2">complexes were prepared using the methods described above.</td><td colspan="2">as a carrier, cells showed intracellular green fluorescent sig</td></tr><tr><td colspan="2">Human chondrocytes (C2812) were contacted with the com</td><td colspan="2">nals as shown in FIG.14D. This demonstrates efficient uptake</td></tr><tr><td colspan="2">plexes and then the expression levels of miR365 determined.</td><td colspan="2">of RNT/GAPDH molecular beacon complexes by chicken</td></tr><tr><td colspan="2">Briefly, total RNA was extracted from cells using a commer</td><td>chondrocytes.</td><td></td></tr><tr><td colspan="2">cially available kit by following the manufacturers instruc</td><td></td><td></td></tr><tr><td colspan="2">tions. Then, the RNA was reverse transcribed using the mis</td><td></td><td>Example 9</td></tr><tr><td colspan="2">cript reverse transcription kit and analyzed by real-time PCR</td><td></td><td></td></tr><tr><td colspan="2">using the appropriate miscript primer assay as per the manu</td><td colspan="2">Mouse Chondrocytes Transfected with RNT/Probe</td></tr><tr><td colspan="2">facturers instructions. For gene expression assay, the same</td><td></td><td>Complexes</td></tr><tr><td colspan="2">amount of RNA was used for each sample. The 18 S RNA was</td><td></td><td></td></tr><tr><td colspan="2">amplified at the same time and used as an internal control. As</td><td style="text-align: right">0106</td><td>To test whether RNT can carry a nucleic acid probe,</td></tr><tr><td colspan="2">shown in FIG. 12B, the TBL/miR365 inhibitor complexes</td><td colspan="2">Such as a molecular beacon capable of hybridizing with or</td></tr><tr><td colspan="2">successfully delivered miR365 inhibitor into the cells and the</td><td colspan="2">otherwise binding to a target gene, RNT/molecular beacon</td></tr><tr><td colspan="2">delivered miR365 inhibitor was functional to decrease</td><td colspan="2">complexes were prepared using the methods described above.</td></tr><tr><td colspan="2">miR365 gene expression. As indicated in a comparison</td><td colspan="2">Primary mouse chondrocytes were incubated with RNT/</td></tr><tr><td colspan="2">between FIG. 12A and FIG.12B, the miR365 inhibitor deliv</td><td colspan="2">miR365 molecular beacon targeting miR365 expression</td></tr><tr><td colspan="2">ered using rosette nanotubes made from the TBL decreased</td><td colspan="2">complex for 24 hours and observed by confocal microscopy.</td></tr><tr><td colspan="2">the miR365 expression to a greater extent than the miR365</td><td colspan="2">Briefly, the cells were washed twice with PBS and then fixed</td></tr><tr><td colspan="2">inhibitor delivered using rosette nanotubes made from the</td><td colspan="2">in 4% formalin for confocal microscopy. FIG. 15 depicts light</td></tr><tr><td>RNT.</td><td></td><td colspan="2">(A and C) and fluorescent (Band D) pictures of chondrocytes</td></tr><tr><td></td><td></td><td colspan="2">cultured with only miR365 molecular beacon (A and B) or</td></tr><tr><td></td><td>Example 7</td><td colspan="2">with RNT/miR365 molecular beacon complex (C and D). As</td></tr><tr><td></td><td></td><td colspan="2">shown in FIG. 15B, fluorescence labeled miR365 molecular</td></tr><tr><td colspan="2">Mouse Chondrocytes (ADTC5) Transfected with</td><td colspan="2">beacon alone was notable to enter the cells. After incubation</td></tr><tr><td></td><td>RNT/Probe Complexes</td><td colspan="2">offluorescent labeled miR365 molecular beacon with RNT as</td></tr><tr><td></td><td></td><td colspan="2">a carrier, cells showed intracellular green fluorescent signals</td></tr><tr><td style="text-align: right">0104.</td><td>To test whether RNT can carry a nucleic acid probe,</td><td colspan="2">as shown in FIG. 15D. This demonstrates efficient uptake of</td></tr><tr><td colspan="2">Such as a molecular beacon capable of hybridizing with or</td><td colspan="2">RNT/miR365 molecular beacon complexes by mouse chon</td></tr><tr><td colspan="2">otherwise binding to a target gene, RNT/molecular beacon</td><td>drocytes.</td><td></td></tr><tr><td colspan="2">complexes were prepared using the methods described above.</td><td></td><td></td></tr><tr><td colspan="2">Mouse chondrocytes (ADTC5) were incubated with RNT/</td><td></td><td>Example 10</td></tr><tr><td colspan="2">GAPDH molecular beacon targeting GAPDH expression</td><td></td><td></td></tr><tr><td colspan="2">complex for 24 hours and observed by confocal microscopy.</td><td></td><td>Additional Cells Transfected with RNT/Probe</td></tr><tr><td colspan="2">Briefly, the cells were washed twice with PBS and then fixed</td><td></td><td>Complexes</td></tr><tr><td colspan="2">in 4% formalin, for confocal. Microscopy. FIG. 13 depicts</td><td></td><td></td></tr><tr><td colspan="2">light (A and C) and fluorescent (B and D) pictures of chon</td><td style="text-align: right">0107</td><td>To test whether RNT can carry a nucleic acid into</td></tr><tr><td colspan="2">drocytes cultured with only the GAPDH molecular beacon (A</td><td colspan="2">various cells, RNT/FITC-siRNA complexes were prepared</td></tr><tr><td colspan="2">and B) or with RNT/GAPDH molecular beacon complex (C</td><td colspan="2">using the methods described above. The RNT/FITC-siRNA</td></tr><tr><td colspan="2">and D). As shown in FIG. 13B, fluorescence labeled GAPDH</td><td colspan="2">complexes were separately incubated for 24 hours with pri</td></tr><tr><td colspan="2">molecular beacon alone was notable to enter the cells. After</td><td>mary</td><td>human fibroblasts, primary pig fibroblasts, human</td></tr><tr><td colspan="2">incubation of fluorescent labeled GAPDH molecular beacon</td><td colspan="2">breast cancer cell line MCF7, ratastrocyte cell line CRL2005,</td></tr><tr><td colspan="2">with RNT as a carrier, cells showed intracellular green fluo</td><td colspan="2">human chondrosarcoma cells, mouse macrophage cell line</td></tr><tr><td colspan="2">rescent signals as shown in FIG. 13D. This demonstrates</td><td colspan="2">RAW264.7, and primary chicken liver cells. The transfected</td></tr><tr><td colspan="2">efficient uptake of RNT/GAPDH molecular beacon com</td><td colspan="2">cells were washed, fixed and stained as previously described.</td></tr><tr><td colspan="2">plexes by mouse chondrocytes.</td><td colspan="2">Fluorescence microscopy of the treated cells revealed inter</td></tr><tr><td></td><td></td><td colspan="2">nalized RNT/siRNA.</td></tr><tr><td></td><td>Example 8</td><td></td><td></td></tr><tr><td></td><td></td><td style="text-align: right">0.108</td><td>FIG. 16 depicts light (A and C) and fluorescent (B</td></tr><tr><td colspan="2">Chicken Primary Chondrocytes Transfected with</td><td colspan="2">and D) pictures of primary human fibroblasts cultured with</td></tr><tr><td></td><td>RNT/Probe Complexes</td><td colspan="2">only FITC-siRNA (A and B) or with RNT/FITC-siRNA com</td></tr><tr><td></td><td></td><td colspan="2">plex (C and D). As shown in FIG. 16B, FITC-siRNA alone</td></tr><tr><td style="text-align: right">0105</td><td>To test whether RNT can carry a nucleic acid probe,</td><td colspan="2">was not able to enter the cells. After incubation of FITC</td></tr><tr><td colspan="2">Such as a molecular beacon capable of hybridizing with or</td><td colspan="2">siRNA with RNT as a carrier, cells showed intracellular green</td></tr><tr><td colspan="2">otherwise binding to a target gene, RNT/molecular beacon</td><td colspan="2">fluorescent signals as shown in FIG.16D. This demonstrates</td></tr><tr><td colspan="2">complexes were prepared using the methods described above.</td><td colspan="2">efficient uptake of RNT/FITC-siRNA complexes by primary</td></tr><tr><td colspan="2">Chicken primary chondrocytes were incubated with RNT/</td><td>human fibroblasts.</td><td></td></tr></table></page>
<page number="38">
<table data-filename="Qian Chen - 2014 - NANOTUBES AS CARRIERS OF NUCLEIC ACIDS INTO CELLS , Patent App(2).pdf" data-page="38" data-table="1"><tr><td>US 2014/0171482 A1</td><td></td><td>Jun. 19, 2014</td></tr><tr><td>0109 FIG. 17 depicts light (A and C) and fluorescent (B</td><td colspan="2">30 ul saline solution. The left femur of a 3 month old male</td></tr><tr><td>and D) pictures of primary pig fibroblasts cultured with only</td><td colspan="2">mouse was injected with the RNT/GAPDH molecular beacon</td></tr><tr><td>FITC-siRNA (A and B) or with RNT/FITC-siRNA complex</td><td colspan="2">complex in a 30 ul saline solution. After injection, fluores</td></tr><tr><td>(Cand D). As shown in FIG.17B, FITC-siRNA alone was not</td><td colspan="2">cence molecular tomography was used to measure the fluo</td></tr><tr><td>able to enter the cells. After incubation of FITC-siRNA with</td><td colspan="2">rescence of the molecular beacons at 30 minutes, 1 day, 3</td></tr><tr><td>RNT as a carrier, cells showed intracellular green fluorescent</td><td colspan="2">days, 5 days and 7 days. FIG. 23 shows a significantly higher</td></tr><tr><td>signals as shown in FIG. 16D. This demonstrates efficient</td><td colspan="2">fluorescence signal from the left femur which was injected</td></tr><tr><td>uptake of RNT/FITC-siRNA complexes by primary pig</td><td colspan="2">with the RNT/molecular beacon complex compared to the</td></tr><tr><td>fibroblasts.</td><td colspan="2">right femur which was injected with the molecular beacon</td></tr><tr><td>0110 FIG. 18 depicts light (A and C) and fluorescent (B</td><td colspan="2">only. This demonstrates that the RNTs were able to deliver the</td></tr><tr><td>and D) pictures of human breast cancer cell line MCF7 cul</td><td colspan="2">molecular beacons into cells in vivo.</td></tr><tr><td>tured with only FITC-siRNA (A and B) or with RNT/FITC</td><td></td><td></td></tr><tr><td>siRNA complex (C and D). As shown in FIG. 18B, FITC</td><td></td><td>Example 12</td></tr><tr><td>siRNA alone was notable to enter the cells. After incubation</td><td></td><td></td></tr><tr><td>of FITC-siRNA with RNT as a carrier, cells showed intrac</td><td></td><td>Comparison with Lipofectamine</td></tr><tr><td>ellular green fluorescent signals as shown in FIG. 18D. This</td><td style="text-align: right">0116.</td><td>The ability of RNTs to deliversiRNA was compared</td></tr><tr><td>demonstrates efficient uptake of RNT/FITC-siRNA com</td><td colspan="2">with that of lipofectamine. Briefly, RNT/fluorescence labeled</td></tr><tr><td>plexes by human breast cancer cell line MCF7.</td><td colspan="2">siRNA were prepared using the methods mentioned above</td></tr><tr><td>0111 FIG. 19 depicts light (A and C) and fluorescent (B</td><td colspan="2">and Lipofectamine/fluorescence labeled siRNA complexes</td></tr><tr><td>and D) pictures of rat astrocyte cell line CRL2005 cultured</td><td colspan="2">were prepared as per the standard commercially available</td></tr><tr><td>with only FITC-siRNA (A and B) or with RNT/FITC-siRNA</td><td colspan="2">protocol. Mouse chondrocytes (ADTC5) were incubated</td></tr><tr><td>complex (C and D). As shown in FIG. 19B, FITC-siRNA</td><td colspan="2">with RNA only, RNT/RNA and Lipofectamine/RNA for 24</td></tr><tr><td>alone was not able to enter the cells. After incubation of</td><td></td><td></td></tr><tr><td></td><td colspan="2">hours. Then, the cells were washed with PBS, detached from</td></tr><tr><td>FITC-siRNA with RNT as a carrier, cells showed intracellu</td><td colspan="2">the culture dishes and fixed by 4% formalin. Flow cytometry</td></tr><tr><td>lar green fluorescent signals as shown in FIG. 19D. This</td><td colspan="2">was used to determine the percentage of fluorescent cells.</td></tr><tr><td>demonstrates efficient uptake of RNT/FITC-siRNA com</td><td colspan="2">Fluorescence positive cells demonstrated the uptake of</td></tr><tr><td>plexes by rat astrocyte cell line CRL2005.</td><td colspan="2">siRNA. Results demonstrated that RNTS deliver siRNA into</td></tr><tr><td>0112 FIG. 20 depicts light (A and C) and fluorescent (B</td><td colspan="2">cells while siRNA alone was not capable of entering cells.</td></tr><tr><td>and D) pictures of human chondrosarcoma cells cultured with</td><td colspan="2">Flow cytometry data as depicted in FIG. 24 shows that deliv</td></tr><tr><td>only FITC-siRNA (A and B) or with RNT/FITC-siRNA com</td><td colspan="2">ery of siRNA into cells was as good as or better than lipo</td></tr><tr><td>plex (C and D). As shown in FIG. 20B, FITC-siRNA alone</td><td colspan="2">fectamine. Especially, RNTs showed a more even distribution</td></tr><tr><td>was not able to enter the cells. After incubation of FITC</td><td colspan="2">of fluorescence among cells.</td></tr><tr><td>siRNA with RNT as a carrier, cells showed intracellular green</td><td style="text-align: right">0117</td><td>To compare the ability of RNT and lipofectamine to</td></tr><tr><td>fluorescent signals as shown in FIG. 20D. This demonstrates</td><td colspan="2">deliver a GAPDH molecular beacon, RNT/GAPDH molecu</td></tr><tr><td>efficient uptake of RNT/FITC-siRNA complexes by human</td><td colspan="2">lar beacon complexes were prepared using methods</td></tr><tr><td>chondrosarcoma cells.</td><td colspan="2">described above and Lipofectamine/GAPDH molecular bea</td></tr><tr><td>0113 FIG. 21 depicts light (A and C) and fluorescent (B</td><td colspan="2">con complexes were prepared as per the standard commer</td></tr><tr><td>and D) pictures of mouse macrophage cell line RAW264.7</td><td colspan="2">cially available protocol. Primary mouse chondrocytes were</td></tr><tr><td>cultured with only FITC-siRNA (A and B) or with RNT/</td><td colspan="2">incubated with GAPDH molecular beacon, RNT/GAPDH</td></tr><tr><td>FITC-siRNA complex (C and D). As shown in FIG. 21B,</td><td colspan="2">molecular beacon complexes, and Lipofectamine/GAPDH</td></tr><tr><td>FITC-siRNA alone was not able to enter the cells. After</td><td colspan="2">molecular beacon complexes for 24 hours and observed by</td></tr><tr><td>incubation of FITC-siRNA with RNT as a carrier, cells</td><td colspan="2">confocal microscopy. As shown in FIG. 25, RNTS demon</td></tr><tr><td>showed intracellular green fluorescent signals as shown in</td><td>strated</td><td>a significantly better delivery ability to deliver</td></tr><tr><td>FIG. 21D. This demonstrates efficient uptake of RNT/FITC</td><td colspan="2">molecular beacons into chondrocytes that lipofectamine at</td></tr><tr><td>siRNA complexes by mouse macrophage cell line RAW264.</td><td>the same dose.</td><td></td></tr><tr><td style="text-align: right">7.</td><td></td><td></td></tr><tr><td>0114 FIG. 22 depicts light (A and C) and fluorescent (B</td><td></td><td>Example 13</td></tr><tr><td>and D) pictures of primary chicken liver cells cultured with</td><td></td><td></td></tr><tr><td>only FITC-siRNA (A and B) or with RNT/FITC-siRNA com</td><td colspan="2">Downstream Gene Expression Comparison with</td></tr><tr><td>plex (C and D). As shown in FIG. 22B, FITC-siRNA alone</td><td></td><td>Lipofectamine</td></tr><tr><td>was not able to enter the cells. After incubation of FITC</td><td></td><td></td></tr><tr><td>siRNA with RNT as a carrier, cells showed intracellular green</td><td colspan="2">0118. The ability of RNTs, TBLs and lipofectamine todeliver miR365 mimic into human chondrocytes (C2812) and</td></tr><tr><td>fluorescent signals as shown in FIG.22D. This demonstrates</td><td colspan="2">to influence expression of the downstream gene RUNX2 was</td></tr><tr><td>efficient uptake of RNT/FITC-siRNA complexes by primarychicken liver cells.</td><td colspan="2">determined. Briefly, total RNA was extracted from cells using</td></tr><tr><td></td><td colspan="2">a commercially available kit by following the manufacturers</td></tr><tr><td>Example 11</td><td colspan="2">instructions. Then, the RNA was reverse transcribed using the</td></tr><tr><td></td><td colspan="2">miscript reverse transcription kit and analyzed by real-time</td></tr><tr><td></td><td colspan="2">PCR using the appropriate miscript primer assay as per the</td></tr><tr><td>In Vivo Delivery of RNT/Probe Complexes to Cells</td><td colspan="2">manufacturers instructions. For gene expression assay, the</td></tr><tr><td>0115 To test whether RNT can carry nucleic acids to cells</td><td colspan="2">same amount of RNA was used for each sample. The 18 S</td></tr><tr><td>in an animal in vivo, RNT/GAPDH molecular beacon target</td><td colspan="2">RNA was amplified at the same time and used as an internal</td></tr><tr><td>ing GAPDH expression was prepared using the methods</td><td colspan="2">control. RNT/miR365 mimic and TBL/miR365 mimic com</td></tr><tr><td>described above. The right femur of a 3 month old male</td><td colspan="2">plexes were prepared using the methods described herein and</td></tr><tr><td>mouse was injected with the GAPDH molecular beacon in a</td><td colspan="2">lipofectamine/miR365 mimic was prepared as the standard</td></tr></table></page>
<page number="39">
<table data-filename="Qian Chen - 2014 - NANOTUBES AS CARRIERS OF NUCLEIC ACIDS INTO CELLS , Patent App(2).pdf" data-page="39" data-table="1"><tr><td colspan="5">US 2014/0171482 A1</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">Jun. 19, 2014</td></tr><tr><td colspan="11">commercially available protocol. As shown in FIG. 26, deliv</td><td colspan="5">3. The method of claim 1 wherein the nanotube is formed</td></tr><tr><td colspan="11">ery of miR365 mimic into cells using RNTs and TBLs</td><td colspan="5">from the self-assembly of compounds having the formula</td></tr><tr><td colspan="11">increased expression of the downstream gene RUNX2 and to</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="10">a greater extent compared with lipofectamine.</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>O</td><td>NH2</td><td></td><td></td></tr><tr><td colspan="5">0119 Given the benefit</td><td colspan="2">of the</td><td colspan="3">above disclosure</td><td>and</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="11">description of exemplary embodiments, it will be apparent to</td><td>HN</td><td></td><td>NN</td><td></td><td></td></tr><tr><td colspan="11">those skilled in the art that numerous alternative and different</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="11">embodiments are possible in keeping with the general prin</td><td>ls</td><td></td><td></td><td>1s</td><td></td></tr><tr><td colspan="11">ciples of the invention disclosed here. Those skilled in this art</td><td>HN</td><td>X</td><td>N</td><td>O</td><td></td></tr><tr><td colspan="11">will recognize that all such various modifications and alter</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="11">native embodiments are within the true scope and spirit of the</td><td>R</td><td></td><td>R</td><td></td><td></td></tr><tr><td>invention. While</td><td colspan="5">the invention</td><td colspan="3">has been</td><td>illustrated</td><td>and</td><td></td><td></td><td>Y</td><td></td><td></td></tr><tr><td colspan="11">described in detail in the drawings and foregoing description,</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="11">Such illustration and description is to be considered as exem</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="11">plary and not restrictive in character, it being understood that,</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="8">only the preferred embodiments have</td><td colspan="2">been shown</td><td>and</td><td colspan="2">whereinX is CH or nitrogen; R</td><td colspan="3">is hydrogen or a linker group;</td></tr><tr><td colspan="11">described and that all changes and modifications that come</td><td colspan="5">Y is absent when R is hydrogen or is an amino acid or</td></tr><tr><td colspan="11">within the spirit of the invention are desired to be protected.</td><td colspan="5">polypeptide having an amino group covalently bound to an</td></tr><tr><td colspan="11">The appended claims are intended to cover all such modifi</td><td colspan="5">C-carbon of the amino acid and the amino group is covalently</td></tr><tr><td colspan="11">cations and alternative embodiments. It should be understood</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="11">that the use of a singular indefinite or definite article (e.g., “a.</td><td colspan="3">bound to the linker group R, and Raliphatic moiety; and salts thereof.</td><td colspan="2">is hydrogen or an</td></tr><tr><td colspan="11">“an.” “the etc.) in this disclosure and in the following claims</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="11">follows the traditional approach in patents of meaning “at</td><td colspan="5">4. The method of claim 1 wherein the one or more nucleic</td></tr><tr><td colspan="11">least one' unless in a particular instance it is clear from</td><td colspan="5">acids include DNA, RNA, a gene, a gene fragment, an exon,</td></tr><tr><td colspan="11">context that the term is intended in that particular instance to</td><td colspan="5">an intron, intergenic DNA, heterochromatic DNA, messenger</td></tr><tr><td colspan="11">mean specifically one and only one. Likewise, the term "com</td><td colspan="3">RNA, transfer RNA, interference</td><td colspan="2">RNA, dsRNA, ssRNA,</td></tr><tr><td colspan="11">prising is open ended, not excluding additional items, fea</td><td>saRNA, siRNA, miRNA,</td><td colspan="4">ribosomal RNA, a ribozyme,</td></tr><tr><td colspan="4">tures, components, etc.</td><td colspan="6">References identified herein</td><td>are</td><td colspan="5">cDNA, a recombinant polynucleotide, a branched polynucle</td></tr><tr><td colspan="11">expressly incorporated herein by reference in their entireties</td><td colspan="5">otide, a plasmid, a vector, isolated DNA of a sequence, iso</td></tr><tr><td colspan="5">unless otherwise indicated.</td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="5">lated RNA of a sequence, a nucleic acid probe, a molecular</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>beacon or a primer.</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="11">1. A method of delivering one or more nucleic acids into a</td><td colspan="5">5. The method of claim 1 wherein the one or more nucleic</td></tr><tr><td colspan="11">cell comprising contacting the cell with a complex of a rosette</td><td colspan="5">acids includes siRNA having between about 10 to about 30</td></tr><tr><td colspan="11">nanotube and the one or more nucleic acids in a manner to</td><td>nucleic acids in length.</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="6">deliver the complex into the cell.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>6. The method of claim</td><td style="text-align: right">1</td><td colspan="2">wherein the cells</td><td>includes an</td></tr><tr><td colspan="11">2. The method of claim 1 wherein the nanotube is formed</td><td colspan="2">animal, plant or bacterial cell.</td><td></td><td></td><td></td></tr><tr><td colspan="11">from the self-assembly of compounds having the formula</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="5">7. A method of treating an individual requiring treatment</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="5">comprising administering a complex of a rosette nanotube</td></tr><tr><td></td><td colspan="2">O</td><td></td><td colspan="2">NH2</td><td></td><td></td><td></td><td></td><td></td><td colspan="5">and one or more nucleic acids to the individual in a manner to</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="5">deliver the one or more nucleic acids into cells within the</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="5">individual and wherein the cells either express the one or</td></tr><tr><td>HN</td><td></td><td></td><td></td><td colspan="2">NN</td><td></td><td></td><td></td><td></td><td></td><td colspan="5">more nucleic acids in a therapeutic manner or the one or more</td></tr><tr><td colspan="2">ls</td><td></td><td></td><td></td><td style="text-align: right" colspan="2">1.</td><td></td><td></td><td></td><td></td><td colspan="5">nucleic acids inhibit expression of one or more proteins</td></tr><tr><td>I</td><td></td><td>X</td><td></td><td>N</td><td></td><td>O</td><td></td><td></td><td></td><td></td><td colspan="3">within the cells in a therapeutic manner.</td><td></td><td></td></tr><tr><td>R</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="5">8. A method of making a complex comprising</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>O</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="5">mixing together rosette nanotubes and one or more nucleic</td></tr><tr><td></td><td></td><td colspan="2">+HN</td><td></td><td></td><td></td><td>l</td><td></td><td></td><td></td><td colspan="5">acids in aqueous media under conditions which cause</td></tr><tr><td style="text-align: right">1</td><td>R</td><td style="text-align: right">1</td><td></td><td colspan="4">n1n N</td><td>N</td><td></td><td></td><td colspan="5">the rosette nanotubes to combine with the one or more</td></tr><tr><td>Y</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="5">nucleic acids to form a stable complex in aqueous media.</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>h</td><td colspan="2">N</td><td></td><td>NH2</td><td></td><td colspan="4">9. A product made by the process comprising</td><td></td></tr><tr><td></td><td></td><td></td><td>R</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="5">mixing together rosette nanotubes and one or more nucleic</td></tr><tr><td></td><td></td><td></td><td></td><td>NNH</td><td></td><td>NH</td><td></td><td>O</td><td></td><td></td><td colspan="5">acids in aqueous media under conditions which cause</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="5">the rosette nanotubes to combine with the one or more</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="5">nucleic acids to form a stable complex in aqueous media.</td></tr><tr><td colspan="11">whereinX is CH or nitrogen; R is hydrogen or a linker group;</td><td colspan="5">10. A complex comprising a rosette nanotube including</td></tr><tr><td colspan="3">Y is absent when R</td><td colspan="8">is hydrogen or is an amino acid or</td><td>one or more nucleic acids.</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="11">polypeptide having an amino group covalently bound to an</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="11">C-carbon of the amino acid and the amino group is covalently</td><td colspan="5">11. A complex comprising one or more nucleic acids and a</td></tr><tr><td colspan="11">bound to the linker group R, and R is hydrogen or an</td><td colspan="5">rosette nanotube formed from the self assembly of com</td></tr><tr><td colspan="7">aliphatic moiety; and salts thereof.</td><td></td><td></td><td></td><td></td><td>pounds having the formula</td><td></td><td></td><td></td><td></td></tr></table></page>
<page number="40">
<table data-filename="Qian Chen - 2014 - NANOTUBES AS CARRIERS OF NUCLEIC ACIDS INTO CELLS , Patent App(2).pdf" data-page="40" data-table="1"><tr><td colspan="2">US 2014/0171482 A1</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Jun. 19, 2014</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">15</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="5">bound to the linker group R, and R</td><td></td><td>is hydrogen or an</td></tr><tr><td>O</td><td></td><td>NH2</td><td></td><td></td><td></td><td colspan="5">aliphatic moiety; and salts thereof,</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="7">and one or more compounds having the formula</td></tr><tr><td>HN</td><td colspan="2">NN</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>ins,</td><td colspan="2">1s.</td><td></td><td></td><td></td><td></td><td>O</td><td></td><td>NH2</td><td></td><td></td><td></td></tr><tr><td>l,</td><td></td><td></td><td></td><td></td><td></td><td>HN</td><td></td><td></td><td colspan="2">NN</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>O</td><td></td><td></td><td colspan="2">ls</td><td></td><td></td><td>1s</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>I</td><td>X</td><td></td><td>N</td><td></td><td>O</td><td></td></tr><tr><td style="text-align: right">-*.</td><td style="text-align: right" colspan="2">-</td><td></td><td></td><td></td><td>R</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>h</td><td>N</td><td></td><td>NH2</td><td></td><td></td><td></td><td></td><td></td><td>O</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">+HN</td><td></td><td></td><td>l</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">-</td><td colspan="3">"n-1N</td><td></td><td>N</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>Y</td><td style="text-align: right">2</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>*in</td><td></td><td>N</td><td></td><td>O</td><td>Y</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>H</td><td>H</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>h</td><td>N</td><td>NH2</td></tr><tr><td colspan="5">wherein X is CH or nitrogen; R is hydrogen or a linker group:</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Y is absent when R</td><td colspan="4">is hydrogen or is an amino acid or</td><td></td><td></td><td></td><td>R</td><td>NN</td><td></td><td>N</td><td>O</td></tr><tr><td colspan="5">polypeptide having an amino group covalently bound to an</td><td></td><td></td><td></td><td></td><td>H</td><td></td><td>H</td><td></td></tr><tr><td colspan="5">C-carbon of the amino acid and the amino group is covalently</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="4">abloiuphnadt itco  mtohiee tlyi;n kaenrd  gsarlotus pt heRr,eo fa.nd R</td><td>is hydrogen or an</td><td></td><td colspan="4">wherein X is CH or nitrogen; R</td><td colspan="3">is hydrogen or a linker group:</td></tr><tr><td colspan="5">12. A complex comprising one or more nucleic acids and a</td><td></td><td colspan="7">pYo liysp eapbtsiednet  hwahveinng  Ran iasm ihyndo rgorgoeunp  ocro viasl eannt laym binoou nadc itod  aonr</td></tr><tr><td colspan="5">rpoosuenttdes  hnaavniontgu bteh e ffoorrmmeudl afrom the self assembly of com</td><td></td><td colspan="7">C-carbon of the amino acid and the amino group is covalently</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="5">bound to the linker group R, and R</td><td></td><td>is hydrogen or an</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="5">aliphatic moiety; and salts thereof.</td><td></td><td></td></tr><tr><td></td><td></td><td>O</td><td>NH2</td><td></td><td></td><td colspan="7">14. The method of claim 2 wherein the aliphatic moiety is</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="7">a straight chain or a branched alkyl group being Saturated or</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>unsaturated.</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>HN</td><td>NN</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="7">15. The method of claim 3 wherein the aliphatic moiety is</td></tr><tr><td></td><td>ls</td><td></td><td style="text-align: right">1.</td><td></td><td></td><td colspan="7">a straight chain or a branched alkyl group being Saturated or</td></tr><tr><td>HN</td><td></td><td>X</td><td>N</td><td></td><td>O</td><td>unsaturated.</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>R</td><td></td><td></td><td>R2</td><td></td><td></td><td colspan="7">16. The complex of claim 11 wherein the aliphatic moiety</td></tr><tr><td></td><td></td><td></td><td>Y</td><td></td><td></td><td colspan="7">is a straight chain or a branched alkyl group being Saturated or</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>unsaturated.</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="7">17. The complex of claim 12 wherein the aliphatic moiety</td></tr><tr><td colspan="5">whereinX is CH or nitrogen; R is hydrogen or a linker group;</td><td></td><td colspan="7">is a straight chain or a branched alkyl group being Saturated or</td></tr><tr><td>Y is absent when R</td><td colspan="4">is hydrogen or is an amino acid or</td><td></td><td>unsaturated.</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="5">polypeptide having an amino group covalently bound to an</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="5">C-carbon of the amino acid and the amino group is covalently</td><td></td><td colspan="7">18. The complex of claim 13 wherein the aliphatic moiety</td></tr><tr><td colspan="4">bound to the linker group R, and R</td><td>is hydrogen or an</td><td></td><td colspan="7">is a straight chain or a branched alkyl group being Saturated or</td></tr><tr><td colspan="3">aliphatic moiety; and salts thereof.</td><td></td><td></td><td></td><td>unsaturated.</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="5">13. A complex comprising one or more nucleic acids and a</td><td></td><td colspan="7">19. The method of claim 2 wherein the linker group is</td></tr><tr><td colspan="5">rosette nanotube formed from the self assembly in aqueous</td><td></td><td colspan="7">(CH), where n is an integer of 1, 2, 3, or 4, (CH2)CO,</td></tr><tr><td colspan="5">media of one or more compounds having the formula</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>O</td><td>NH2</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>NH</td></tr><tr><td></td><td></td><td>HN</td><td>NN</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>ls</td><td></td><td>1s</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>HN</td><td></td><td>X</td><td>N</td><td></td><td>O</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>R</td><td></td><td></td><td>R</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="4">A-.</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Y</td><td></td><td></td><td></td><td></td><td colspan="2">OH</td><td></td><td></td><td></td></tr><tr><td colspan="5">whereinX is CH or nitrogen; R is hydrogen or a linker group;</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Y is absent when R</td><td colspan="4">is hydrogen or is an amino acid or</td><td></td><td colspan="4">UC</td><td></td><td></td><td></td></tr><tr><td colspan="5">polypeptide having an amino group covalently bound to an</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="5">C-carbon of the amino acid and the amino group is covalently</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table></page>
<page number="41">
<table data-filename="Qian Chen - 2014 - NANOTUBES AS CARRIERS OF NUCLEIC ACIDS INTO CELLS , Patent App(2).pdf" data-page="41" data-table="1"><tr><td>US 2014/0171482 A1</td><td></td><td></td><td></td><td></td><td></td><td></td><td>Jun. 19, 2014</td></tr><tr><td></td><td></td><td></td><td style="text-align: right">16</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">-continued</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>O</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>G</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>NH</td><td></td><td>GE)</td><td></td><td>GE</td></tr><tr><td>N</td><td></td><td></td><td></td><td></td><td>NH</td><td></td><td>NH</td></tr><tr><td>H</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>NH</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>GE)</td><td></td><td></td><td></td><td></td><td></td><td>GE</td></tr><tr><td></td><td>O</td><td></td><td></td><td></td><td></td><td></td><td>NH</td></tr><tr><td></td><td></td><td></td><td>GE</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>NH</td><td></td><td></td><td></td><td></td></tr><tr><td>N</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>H</td><td></td><td></td><td></td><td colspan="2">A-</td><td>Me</td><td>x</td></tr><tr><td></td><td>NH</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>GE)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>N-N</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>O</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>g</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>NH</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>NH</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>GE)</td><td></td></tr><tr><td colspan="3">20. The method of claim 3 wherein the linker group is</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="3">(CH), where n is an integer of 1, 2, 3, or 4, (CH2)CO,</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>G</td><td></td><td></td><td>GE)</td><td></td><td></td><td></td><td></td></tr><tr><td>NH</td><td></td><td>NH</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>G</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>NH</td><td></td><td></td><td></td><td></td></tr><tr><td>A-</td><td>Me</td><td>A --&gt;</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>T</td><td></td><td></td><td>t</td><td colspan="4">22. The method of claim 12 wherein the linker group is</td></tr><tr><td>O</td><td></td><td></td><td></td><td>(CH),</td><td colspan="3">where n is an integer of 1, 2, 3, or 4, (CH2)CO,</td></tr><tr><td></td><td></td><td></td><td>GE)</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>NH</td><td></td><td></td><td></td><td></td></tr><tr><td>N</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>GEN)H</td><td></td><td></td><td>x- GE)</td><td></td><td></td><td>GE</td></tr><tr><td></td><td>O</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>GE)</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>NH</td><td></td><td></td><td></td><td>GE)</td></tr><tr><td>N</td><td></td><td></td><td></td><td></td><td></td><td></td><td>NH</td></tr><tr><td>H</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>NH</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>GE)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>OH</td><td>Me</td><td></td></tr><tr><td colspan="3">21. The method of claim 11 wherein the linker group is</td><td></td><td></td><td></td><td>GE)</td><td></td></tr><tr><td colspan="3">(CH), where n is an integer of 1, 2, 3, or 4, (CH2)CO,</td><td></td><td></td><td></td><td></td><td></td></tr></table></page>
<page number="42">
<table data-filename="Qian Chen - 2014 - NANOTUBES AS CARRIERS OF NUCLEIC ACIDS INTO CELLS , Patent App(2).pdf" data-page="42" data-table="1"><tr><td>US 2014/0171482 A1</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">Jun. 19, 2014</td></tr><tr><td>-continued</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>O</td><td></td><td></td><td>O</td><td colspan="2">NH2</td><td></td><td></td><td></td></tr><tr><td></td><td>GE)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>NH</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>N</td><td colspan="2">HN</td><td></td><td colspan="2">NN</td><td></td><td></td><td></td></tr><tr><td></td><td>NH</td><td colspan="3">ls</td><td></td><td colspan="2">1s</td><td></td><td></td></tr><tr><td></td><td>GE)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>I</td><td></td><td>X</td><td>N</td><td></td><td>O</td><td></td><td></td></tr><tr><td></td><td></td><td>R</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>O</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>+HN</td><td></td><td></td><td></td><td>l</td><td></td></tr><tr><td></td><td></td><td></td><td>Y</td><td style="text-align: right">2-</td><td colspan="2">"n-1N</td><td></td><td>N</td><td></td></tr><tr><td></td><td></td><td>Y</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>h</td><td>N</td><td></td><td>NH2</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>R</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>NN</td><td></td><td>N</td><td>O</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>H</td><td></td><td>H</td><td></td><td></td></tr><tr><td colspan="2">23. The method of claim 13 wherein the linker group is</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">(CH), where n is an integer of 1, 2, 3, or 4, (CH2)CO,</td><td colspan="6">wherein X is CH or nitrogen; R</td><td colspan="2">is hydrogen or a linker</td></tr><tr><td></td><td></td><td colspan="8">group: Y is absent when R is hydrogen or is an amino</td></tr><tr><td></td><td></td><td colspan="8">acid or polypeptide having an amino group covalently</td></tr><tr><td></td><td></td><td colspan="8">bound to an O-carbon of the amino acid and the amino</td></tr><tr><td></td><td></td><td colspan="8">group is covalently bound to the linker group R, and R.</td></tr><tr><td></td><td></td><td colspan="8">is hydrogen oran aliphatic moiety, such alkyl, straight or</td></tr><tr><td></td><td></td><td>branched</td><td colspan="5">chain, Saturated or</td><td colspan="2">unsaturated; and salts</td></tr><tr><td></td><td></td><td>thereof,</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="8">and one or more nucleic acids in aqueous media and soni</td></tr><tr><td></td><td></td><td colspan="8">cating the mixture to cause the compounds to combine</td></tr><tr><td></td><td></td><td colspan="4">with the one or more</td><td colspan="2">nucleic</td><td>acids to</td><td>form a stable</td></tr><tr><td></td><td></td><td colspan="5">complex in aqueous media.</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="8">25. The method of claim 24 wherein the linker group is</td></tr><tr><td></td><td></td><td colspan="8">(CH), where n is an integer of 1, 2, 3, or 4, (CH2)CO,</td></tr><tr><td colspan="2">24. A method of making a complex comprising mixing</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>together compounds having the formula</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table></page>
<page number="43">
<table data-filename="Qian Chen - 2014 - NANOTUBES AS CARRIERS OF NUCLEIC ACIDS INTO CELLS , Patent App(2).pdf" data-page="43" data-table="1"><tr><td colspan="2">US 2014/0171482 A1</td><td></td><td></td><td></td><td></td><td></td><td></td><td>Jun. 19, 2014</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">18</td><td></td></tr><tr><td></td><td colspan="2">-continued</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="7">26. The method of claim 24 wherein the mixture is soni</td><td></td><td></td></tr><tr><td colspan="2">cated and heated to boiling.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="7">27. A method of making a complex comprising mixing</td><td></td><td></td></tr><tr><td colspan="4">together compounds having the formula</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>O</td><td colspan="2">NH2</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>HN</td><td colspan="2">NN</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>ls</td><td></td><td>-N</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>HN</td><td>X</td><td>N</td><td colspan="2">O</td><td></td><td></td><td></td><td></td></tr><tr><td>R</td><td></td><td>R</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Y</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="7">wherein X is CH or nitrogen; R is hydrogen or a linker group:</td><td></td><td></td></tr><tr><td colspan="7">Y is absent when R is hydrogen or is an amino acid or</td><td></td><td></td></tr><tr><td colspan="7">polypeptide having an amino group covalently bound to an</td><td></td><td></td></tr><tr><td colspan="7">C-carbon of the amino acid and the amino group is covalently</td><td></td><td></td></tr><tr><td colspan="7">bound to the linker group R, and R is hydrogen or an</td><td></td><td></td></tr><tr><td colspan="7">aliphatic moiety, Such as alkyl, straight or branched chain,</td><td></td><td></td></tr><tr><td colspan="4">saturated or unsaturated; and salts thereof</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="7">and one or more nucleic acids in aqueous media and Soni</td><td></td><td></td></tr><tr><td colspan="7">cating the mixture to cause the compounds to combine</td><td></td><td></td></tr><tr><td colspan="3">with the one or more nucleic</td><td>acids</td><td>to</td><td>form</td><td>a</td><td>stable</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">29. The method of claim 27 wherein the mixture is soni</td></tr><tr><td colspan="3">complex in aqueous media.</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>cated and heated to boiling.</td><td></td></tr><tr><td colspan="7">28. The method of claim 26 wherein the linker group is</td><td></td><td></td></tr><tr><td colspan="7">(CH), where n is an integer of 1, 2, 3, or 4, (CH2)CO,</td><td>k .</td><td style="text-align: right">. . .</td></tr></table></page>
</document>
